Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
amyloid peptide Abeta(3-40,42)
Abeta(3[pE]-40,42) + H2O
-
-
-
?
EFRH-NH2
pEFRH-NH2 + H2O
-
-
-
-
?
EFRHHDSGYE-NH2
pEFRHHDSGYE-NH2 + H2O
-
-
-
-
?
Gln
pyroglutamate + NH3
-
-
-
-
?
Gln(3)-amyloid-beta peptide 3-11 amide
?
-
-
-
-
?
Gln(3)-amyloid-beta peptide 3-21 amide
?
-
-
-
-
?
Gln(3)-amyloid-beta peptide 3-40 amide
?
-
-
-
-
?
Gln-2-naphthylamide
2-oxoprolyl-2-naphthylamide + NH3
-
-
-
-
?
Gln-4-methylcoumarinylamide
2-oxoprolyl-4-methylcoumarinylamide + NH3
-
-
-
-
?
Gln-7-amido-4-methylcoumarin
L-pyroglutamyl-4-methylcoumarin-7-amide + NH3
-
-
-
-
?
Gln-7-amido-4-methylcoumarin
pyroglutamic acid-7-amido-4-methylcoumarin + NH3
-
-
-
?
Gln-Ala
Glp-Ala + NH3
-
-
-
-
?
Gln-Ala
pyroglutamic acid-Ala + NH3
-
-
-
-
?
Gln-Ala-Ala-Ala-Ala-NH2
pyroglutamic acid-Ala-Ala-Ala-Ala-NH2 + NH3
-
-
-
-
?
Gln-Ala-Ala-NH2
pyroglutamic acid-Ala-Ala-NH2 + NH3
-
-
-
-
?
Gln-Ala-Ala-Ser-Ala-Ala-NH2
pyroglutamic acid-Ala-Ala-Ser-Ala-Ala-NH2 + NH3
-
-
-
-
?
Gln-Arg-Gly-Ile-NH2
pyroglutamic acid-Arg-Gly-Ile-NH2 + NH3
-
-
-
-
?
Gln-Arg-Tyr-Phe-NH2
pyroglutamic acid-Arg-Tyr-Phe-NH2 + NH3
-
-
-
-
?
Gln-Asn-Gly-Ile-NH2
pyroglutamic acid-Asn-Gly-Ile-NH2 + NH3
-
-
-
-
?
Gln-beta-naphthylamide
pyroglutamic acid-beta-naphthylamide + NH3
-
-
-
-
?
Gln-Gln
5-oxoprolyl-Gln + NH3
-
-
-
-
?
Gln-Gln
L-5-oxoprolyl-Gln + NH3
-
-
-
-
?
Gln-Gln
pGlu-Gln + NH3
-
-
-
-
?
Gln-Gln
pyroglutamic acid-Gln + NH3
Gln-Gln
pyroglutamyl-Gln + NH3
-
-
-
-
?
Gln-Gln-Gln
Glp-Gln-Gln + NH3
-
-
-
-
?
Gln-Gln-Tyr-Phe-NH2
pyroglutamic acid-Gln-Tyr-Phe-NH2 + NH3
-
-
-
-
?
Gln-Glu
pGlu-Glu + NH3
-
-
-
-
?
Gln-Glu
pyroglutamic acid-Glu + NH3
-
-
-
-
?
Gln-Glu-Ala-Ala-NH2
pyroglutamic acid-Glu-Ala-Ala-NH2 + NH3
-
-
-
-
?
Gln-Glu-Ala-Phe-NH2
pyroglutamic acid-Glu-Ala-Phe-NH2 + NH3
-
-
-
-
?
Gln-Glu-Asp-Leu-NH2
pyroglutamic acid-Glu-Asp-Leu-NH2 + NH3
-
-
-
-
?
Gln-Glu-Tyr-Ala-NH2
pyroglutamic acid-Glu-Tyr-Ala-NH2 + NH3
-
-
-
-
?
Gln-Glu-Tyr-NH2
pyroglutamic acid-Glu-Tyr-NH2 + NH3
-
-
-
-
?
Gln-Glu-Tyr-Phe-NH2
pyroglutamic acid-Glu-Tyr-Phe-NH2 + NH3
-
-
-
-
?
Gln-Gly
5-oxoprolyl-Gly + NH3
-
-
-
-
?
Gln-Gly
Glp-Gly + NH3
-
-
-
-
?
Gln-Gly
pGlu-Gly + NH3
-
-
-
-
?
Gln-Gly
pyroglutamic acid-Gly + NH3
-
-
-
-
?
Gln-Gly-Pro
pGlu-Gly-Pro + NH3
-
-
-
-
?
Gln-Gly-Pro
pyroglutamic acid-Gly-Pro + NH3
-
-
-
-
?
Gln-His-Pro
pyroglutamyl-His-Pro
-
-
-
-
?
Gln-His-Pro-NH2
L-5-oxoprolyl-His-Pro-NH2 + NH3
-
-
-
-
?
Gln-His-Tyr-Phe-NH2
pyroglutamic acid-His-Tyr-Phe-NH2 + NH3
-
-
-
-
?
Gln-Lys-Arg-Leu-NH2
pyroglutamic acid-Lys-Arg-Leu-NH2 + NH3
-
-
-
-
?
Gln-NH2
Glp-amide + NH3
-
-
-
-
?
Gln-Phe-Ala
pGlu-Phe-Ala + NH3
-
-
-
-
?
Gln-Phe-Ala-NH2
pyroglutamic acid-Phe-Ala-NH2 + NH3
-
-
-
-
?
Gln-Pro-Tyr-Phe-NH2
pyroglutamic acid-Pro-Tyr-Phe-NH2 + NH3
-
-
-
-
?
Gln-Ser-Tyr-Phe-NH2
pyroglutamic acid-Ser-Tyr-Phe-NH2 + NH3
-
-
-
-
?
Gln-tert-butyl ester
pyroglutamyl-tert-butyl ester + NH3
-
-
-
-
?
Gln-Trp-Ala-NH2
pyroglutamic acid-Trp-Ala-NH2 + NH3
-
-
-
-
?
Gln-Tyr
pyroglutamic acid-Tyr + NH3
-
-
-
-
?
Gln-Tyr-Ala
pGlu-Tyr-Ala + NH3
-
-
-
-
?
Gln-Tyr-Ala
pyroglutamic acid-Tyr-Ala + NH3
-
-
-
-
?
Gln-Tyr-Ala-OH
L-5-oxoprolyl-Tyr-Ala + NH3
-
-
-
-
?
Gln-Val
pyroglutamic acid-Val + NH3
-
-
-
-
?
glucagon(3-29)
?
-
-
-
-
?
H-Gln-7-amido-4-methylcoumarin
5-oxoprolyl-7-amido-4-methylcoumarin + NH3
-
-
-
-
?
H-Gln-beta-naphthylamide
5-oxoprolyl-beta-naphthylamide + NH3
-
-
-
-
?
H-Gln-Glu-OH
5-oxoprolyl-Glu-OH + NH3
-
-
-
-
?
H-Gln-Gly-Pro-OH
5-oxoprolyl-Gly-Pro-OH + NH3
-
-
-
-
?
L-Gln(3)-amyloid-beta peptide 3-42
L-pyroglutamyl(3)-amyloid-beta peptide 3-42 + NH3
-
-
-
-
?
L-Gln-2-naphthylamide
5-oxoprolyl-2-naphthylamide + NH3
L-Gln-2-naphthylamide
L-pyroglutamyl-2-naphthylamide + NH3
-
reaction in cell supernatant is exclusively enzyme-catalyzed
-
-
?
L-Gln-7-amido-4-methylcoumarin
5-oxoprolyl-7-amido-4-methylcoumarin + NH3
-
-
-
?
L-Gln-7-amido-4-methylcoumarin
pyroglutamate-7-amido-4-methylcoumarin + NH3
-
-
-
-
?
L-Gln-Gly
5-oxoprolyl-Gly + NH3
-
-
-
?
L-Gln-Gly-L-Pro
5-oxoprolyl-Gly-L-Pro + NH3
-
-
-
?
L-Gln-L-Gln
5-oxoprolyl-L-Gln + NH3
-
-
-
?
L-Gln-L-Glu
5-oxoprolyl-L-Glu + NH3
-
-
-
?
L-Gln-L-Glu-L-Asp-L-Leu-NH2
5-oxoprolyl-L-Glu-L-Asp-L-Leu-NH2 + NH3
-
-
-
?
L-Gln-L-Lys-L-Arg-L-Leu-NH2
5-oxoprolyl-L-Lys-L-Arg-L-Leu-NH2 + NH3
-
-
-
?
L-Gln-L-Phe-L-Ala-NH2
5-oxoprolyl-L-Phe-L-Ala-NH2 + NH3
-
-
-
?
L-Gln-NH2
L-pyroglutamyl amide + NH3
-
-
-
-
?
L-Glu(3)-amyloid-beta peptide 3-42
L-pyroglutamyl(3)-amyloid-beta peptide 3-42 + H2O
-
-
-
-
?
L-glutaminyl-2-naphthylamide
L-5-oxoprolyl-2-naphthylamide + NH3
-
-
-
-
?
L-glutaminyl-4-methylcoumarinylamide
L-5-oxoprolyl-4-methylcoumarinylamide + NH3
-
-
-
-
?
L-glutaminyl-7-amido-4-methylcoumarin
L-pyroglutamyl-7-amido-4-methylcoumarin + NH3
-
-
-
?
L-glutaminyl-7-amido-4-methylcoumarin
pGlu-7-amido-4-methylcoumarin + NH3
L-glutaminyl-Abeta3-40/42
5-oxoprolyl-Abeta3-40/42 + NH3
amyloid-beta peptide Abeta3-40/42
-
-
r
L-glutaminyl-Abeta3-40/42 peptide
5-oxoprolyl-Abeta3-40/42 peptide + NH3
amyloid-beta peptide Abeta3-40/42
-
-
?
L-glutaminyl-amyloid beta peptide
5-oxoprolyl-amyloid beta peptide + NH3
-
-
-
-
?
L-glutaminyl-beta-naphthylamide
pGlu-beta-naphthylamide + NH3
-
-
-
-
?
L-glutaminyl-CCL2
5-oxoprolyl-CCL2 + NH3
L-glutaminyl-CD47
5-oxoprolyl-CD47 + NH3
-
-
-
?
L-glutaminyl-monocyte chemoattractant protein 1
5-oxoprolyl-monocyte chemoattractant protein 1 + NH3
i.e. MCP-1 or CCL2
-
-
?
L-glutaminyl-monocyte chemoattractant protein 3
5-oxoprolyl-monocyte chemoattractant protein 3 + NH3
i.e. MCP-3 or CCL7
-
-
?
L-glutaminyl-peptide
5-oxoprolyl-peptide + NH3
L-glutaminyl-Phe-Ala
5-oxoprolyl-Phe-Ala + NH3
-
-
-
r
QEDL
pEEDL + NH3
-
-
-
-
?
QEYF
pEEYF + NH3
-
-
-
-
?
QFRH-NH2
pEFRH-NH2 + NH3
-
-
-
-
?
[Gln1]-fertilization promoting peptide
[pyroglutamyl]-fertilization promoting peptide + NH3
-
-
-
-
?
[Gln1]-gastrin
[pyroglutamyl]-gastrin + NH3
-
-
-
-
?
[Gln1]-gonadotropin releasing-hormone
[pyroglutamyl]-gonadotropin releasing-hormone + NH3
-
-
-
-
?
[Gln1]-neurotensin
[pyroglutamyl]-neurotensin + NH3
-
-
-
-
?
[Gln1]-thyrotropin releasing-hormone
[pyroglutamyl]-thyrotropin releasing-hormone + NH3
-
-
-
-
?
additional information
?
-
Gln-Gln
Glp-Gln + NH3
-
-
-
-
?
Gln-Gln
Glp-Gln + NH3
-
-
-
?
Gln-Gln
pyroglutamic acid-Gln + NH3
-
-
-
-
?
Gln-Gln
pyroglutamic acid-Gln + NH3
-
-
-
?
L-Gln-2-naphthylamide
5-oxoprolyl-2-naphthylamide + NH3
-
-
-
-
?
L-Gln-2-naphthylamide
5-oxoprolyl-2-naphthylamide + NH3
-
-
-
?
L-Gln-2-naphthylamide
5-oxoprolyl-2-naphthylamide + NH3
-
-
-
?
L-glutaminyl-7-amido-4-methylcoumarin
pGlu-7-amido-4-methylcoumarin + NH3
-
-
-
-
?
L-glutaminyl-7-amido-4-methylcoumarin
pGlu-7-amido-4-methylcoumarin + NH3
-
-
-
?
L-glutaminyl-CCL2
5-oxoprolyl-CCL2 + NH3
i.e. monocyte chemoattractant protein (MCP-1)
-
-
r
L-glutaminyl-CCL2
5-oxoprolyl-CCL2 + NH3
i.e. monocyte chemoattractant protein (MCP-1), CCL2 is a specific substrate for h-isoQC but not for h-QC
-
-
r
L-glutaminyl-peptide
5-oxoprolyl-peptide + NH3
-
-
-
?
L-glutaminyl-peptide
5-oxoprolyl-peptide + NH3
-
-
-
?
L-glutaminyl-peptide
5-oxoprolyl-peptide + NH3
-
-
-
?
L-glutaminyl-peptide
5-oxoprolyl-peptide + NH3
-
-
-
-
?
L-glutaminyl-peptide
5-oxoprolyl-peptide + NH3
-
-
-
?
L-glutaminyl-peptide
5-oxoprolyl-peptide + NH3
-
-
-
?
L-glutaminyl-peptide
5-oxoprolyl-peptide + NH3
-
-
-
?
L-glutaminyl-peptide
5-oxoprolyl-peptide + NH3
-
-
-
?
L-glutaminyl-peptide
5-oxoprolyl-peptide + NH3
-
-
-
?
L-glutaminyl-peptide
5-oxoprolyl-peptide + NH3
-
-
-
r
L-glutaminyl-peptide
5-oxoprolyl-peptide + NH3
-
-
-
?
L-glutaminyl-peptide
5-oxoprolyl-peptide + NH3
-
thyrotropin-releasing hormone
-
?
L-glutaminyl-peptide
5-oxoprolyl-peptide + NH3
-
the N-terminal formation of 5-oxoproline is a common post-translational event during biosynthesis of a number of peptides
-
-
?
L-glutaminyl-peptide
5-oxoprolyl-peptide + NH3
-
involved in posttranslational modification of the N-terminal glutamine of peptide hormones or neurotransmitters, such as thyrotropin releasing hormone, luteinizing hormone releasing hormone, gastrin, heavy chain of gamma-globulin
-
-
?
additional information
?
-
-
the enzyme may play a key role in posttranslational modification
-
-
?
additional information
?
-
-
enzyme is important during cellular maturation of L-pyroglutamyl-containing peptides
-
-
?
additional information
?
-
-
catalyzes the formation of amyloid-beta3(pE)-40/42 after amyloidogenic processing of amyloid precursor protein
-
-
?
additional information
?
-
orexin A, gastrin, gonadotropin, TRH, MCP-1 to 4, FPP, fibronectin, and neurotensin are substrates of the enzyme
-
-
-
additional information
?
-
cyclization reaction of glutamate and glutamine residues, overview
-
-
-
additional information
?
-
cyclization reaction of glutamate and glutamine residues, overview
-
-
-
additional information
?
-
cyclization reaction of glutamate and glutamine residues, overview. CCL2 is a specific substrate for h-isoQC but not for h-QC
-
-
-
additional information
?
-
cyclization reaction of glutamate and glutamine residues, overview. CCL2 is a specific substrate for h-isoQC but not for h-QC
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(3,4-dichlorophenyl)-2-cyano-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)guanidine
-
(3-(1H-imidazol-1-yl)propyl)-2-cyano-3-(2,3-dihydrobenzo[b][1,4]dioxin-7-yl)guanidine
-
(3-(1H-imidazol-1-yl)propyl)-2-cyano-3-(3,4-dimethoxyphenyl)guanidine
-
(3-(1H-imidazol-1-yl)propyl)-2-cyano-3-(4-(trifluoromethyl)phenyl)guanidine
-
(3-(1H-imidazol-1-yl)propyl)-2-cyano-3-(4-isopropylphenyl)guanidine
-
(3-(1H-imidazol-1-yl)propyl)-2-cyano-3-(4-methoxyphenyl)guanidine
-
(3-(1H-imidazol-1-yl)propyl)-2-cyano-3-(cyclopropylmethyl)guanidine
-
(3-(1H-imidazol-1-yl)propyl)-2-cyano-3-methylguanidine
-
(3-(1H-imidazol-1-yl)propyl)-2-cyano-3-phenylguanidine
-
(3-(1H-imidazol-1-yl)propyl)-3-(4-bromophenyl)-2-cyanoguanidine
-
(3-(4-methyl-1H-imidazol-1-yl)propyl)-2-cyano-3-(2,3-dihydrobenzo[b][1,4]dioxin-7-yl)guanidine
-
(3-(5-methyl-1H-imidazol-1-yl)propyl)-2-cyano-3-(2,3-dihydrobenzo[b][1,4]dioxin-7-yl)guanidine
-
(E)-N1-(5-methyl-1H-imidazol-1-yl)-2-nitro-N'1-[4-(trifluoromethyl)phenyl]ethene-1,1-diamine
-
1,2-di-O-palmitoyl-3-O-(6'-deoxy-6'-sulfo-D-glycopyranosyl)-glycerol
1,4-bis-(imidazol-1-yl)methyl-2,5-dimethylbenzene
-
1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[3-(1H-imidazol-1-yl)propyl]thiourea
-
-
1-(2,4-dimethoxyphenyl)-3-[3-(1H-imidazol-1-yl)propyl]thiourea
-
-
1-(2-oxo-2-phenylethyl)-imidazole
-
1-(3,4-dimethoxybenzyl)-3-[3-(1H-imidazol-1-yl)propyl]thiourea
-
-
1-(3,4-dimethoxyphenyl)-3-(2-[1-(1H-imidazol-1-yl)cyclopropyl]ethyl)thiourea
-
-
1-(3,4-dimethoxyphenyl)-3-(3-(4-methyl-1H-imidazol-1-yl)propyl)thiourea
-
1-(3,4-dimethoxyphenyl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
1-(3,4-dimethoxyphenyl)-3-[(3R)-3-(1H-imidazol-1-yl)butyl]thiourea
-
-
1-(3,4-dimethoxyphenyl)-3-[(3S)-3-(1H-imidazol-1-yl)butyl]thiourea
-
-
1-(3,4-dimethoxyphenyl)-3-[3-(1H-imidazol-1-yl)propyl]thiourea
1-(3,4-dimethoxyphenyl)-3-[3-(1H-imidazol-1-yl)propyl]urea
-
-
1-(3,4-dimethoxyphenyl)-3-[4-(1H-imidazol-1-yl)butyl]thiourea
-
-
1-(3,4-dimethoxyphenyl)-N-(1H-imidazol-1-yl)cyclopropane-1-carbothioamide
-
1-(3,4-dimethoxyphenyl)-N-(3-(4-methyl-1H-imidazol-1-yl)propyl)cyclopropanecarbothioamide
-
1-(3,4-dimethoxyphenyl)-N-(3-(5-methyl-1H-imidazol-1-yl)propyl)cyclopropanecarbothioamide
-
1-(3,4-dimethoxyphenyl)-N-(4-methyl-1H-imidazol-1-yl)cyclopropane-1-carbothioamide
-
1-(3,4-dimethoxyphenyl)-N-(5-methyl-1H-imidazol-1-yl)cyclopropane-1-carbothioamide
-
1-(3,4-dimethoxyphenyl)-N-[3-(1H-imidazol-1-yl)propyl]cyclopropane-1-carbothioamide
-
1-(3,5-dimethoxyphenyl)-3-[3-(1H-imidazol-1-yl)propyl]thiourea
-
-
1-(3-aminopropyl)-imidazole
-
1-(4-acetylphenyl)-3-[3-(1H-imidazol-1-yl)propyl]thiourea
-
-
1-(4-ethoxyphenyl)-3-[3-(1H-imidazol-1-yl)propyl]thiourea
-
-
1-(4-ethylphenyl)-3-[3-(1H-imidazol-1-yl)propyl]thiourea
-
-
1-(6-phenoxyhexyl)-1H-imidazole
-
1-methyl-4-(beta-aminoethyl)-imidazole
-
1-methyl-5-(beta-aminoethyl)-imidazole
-
1-O-linolyl-2-O-palmitoyl-3-O-(6'-deoxy-6'-sulfo-D-glucopyranosyl)-glycerol
1-O-palmitoyl-2-O-linolenyl-3-O-(6'-deoxy-6'-sulfo-D-glucopyranosyl)-glycerol
1-[3-(1H-imidazol-1-yl)propyl]-3-(1-naphthyl)thiourea
-
-
1-[3-(1H-imidazol-1-yl)propyl]-3-(3,4,5-trimethoxyphenyl)thiourea
-
-
1-[3-(1H-imidazol-1-yl)propyl]-3-(3-methoxyphenyl)thiourea
-
-
1-[3-(1H-imidazol-1-yl)propyl]-3-(4-methoxyphenyl)thiourea
-
-
1-[3-(1H-imidazol-1-yl)propyl]-3-(4-methylphenyl)thiourea
-
-
1-[3-(1H-imidazol-1-yl)propyl]-3-[4-(methylthio)phenyl]thiourea
-
-
1-[4-(benzyloxy)phenyl]-3-[3-(1H-imidazol-1-yl)propyl]thiourea
-
-
2,3-dihydro-3-(3-(4-methyl-1H-imidazol-1-yl)propyl)-2-thioxoquinazolin-4(1H)-one
-
2,3-dihydro-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)-2-thioxoquinazolin-4(1H)-one
-
2,3-dihydro-6-methyl-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)-5-phenyl-2-thioxothieno[2,3-d]pyrimidin-4(1H)-one
-
2-(2,3-dimethoxyphenyl)-5,7-dihydroxy-4H-chromen-4-one
87.7% inhibition at 0.1 mM
2-(2,3-dimethoxyphenyl)-7-hydroxy-4H-chromen-4-one
54.3% inhibition at 0.1 mM
2-(2,4-dimethoxyphenyl)-5,7-dihydroxy-4H-chromen-4-one
71.7% inhibition at 0.1 mM
2-(2-fluorophenyl)-5,7-dihydroxy-4H-chromen-4-one
84.2% inhibition at 0.1 mM
2-(2-fluorophenyl)-7-hydroxy-4H-chromen-4-one
60.8% inhibition at 0.1 mM
2-(3,4-dimethoxyphenyl)-7-hydroxy-4H-chromen-4-one
68.3% inhibition at 0.1 mM
2-(3-fluorophenyl)-7-hydroxy-4H-chromen-4-one
63.3% inhibition at 0.1 mM
2-(4-(dimethylamino)phenyl)-7-hydroxy-4H-chromen-4-one
90.3% inhibition at 0.1 mM
2-(4-ethoxyphenyl)-5,7-dihydroxy-4H-1-benzopyran-4-one
-
2-(4-ethoxyphenyl)-5,7-dihydroxy-4H-chromen-4-one
91.5% inhibition at 0.1 mM
2-(4-ethoxyphenyl)-7-hydroxy-4H-chromen-4-one
67.6% inhibition at 0.1 mM
2-(4-ethylphenyl)-5,7-dihydroxy-4H-chromen-4-one
85.2% inhibition at 0.1 mM
2-(4-ethylphenyl)-7-hydroxy-4H-chromen-4-one
79.5% inhibition at 0.1 mM
2-(4-fluorophenyl)-7-hydroxy-4H-chromen-4-one
74.2% inhibition at 0.1 mM
2-(furan-2-yl)-7-hydroxy-4H-chromen-4-one
68.7% inhibition at 0.1 mM
2-(furan-3-yl)-7-hydroxy-4H-chromen-4-one
61.4% inhibition at 0.1 mM
2-cyano(3,4,5-trimethoxyphenyl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)guanidine
-
2-cyano(3-(5-methyl-1H-imidazol-1-yl)propyl)-3-(3,4-dimethylphenyl)guanidine
-
2-cyano-1-[3-(5-methyl-1H-imidazol-1-yl)propyl]-4-phenylbenzene-1-guanidine
-
2-ethyl-4-methyl-imidazole
-
2-methyl-benzylimidazole
-
3,5-diamino-1,2-S4-triazole
-
0.14 mM, 10% inhibition
3-(3-(1H-imidazol-1-yl)propyl)-2,3-dihydro-2-thioxoquinazolin-4(1H)-one
-
3-(3-(1H-imidazol-1-yl)propyl)-2,3-dihydro-7-methyl-2-thioxothieno[3,2-d]pyrimidin-4(1H)-one
-
3-(5-methyl-1H-imidazol-1-yl)-6-phenyl-2-sulfanylidene-2,3-dihydrothieno[2,3-d]pyrimidin-4(1H)-one
-
3-Amino-1,2,4-triazole
-
0.14 mM, 15% inhibition
3-fluoro-3',4'-dimethoxy-N-[3-(4-methyl-1H-imidazol-1-yl)propyl][1,1'-biphenyl]-2-amine
-
3-[(1H-imidazol-1-yl)methyl]aniline
-
3-[3-(1H-imidazol-1-yl)propyl]-2-thioxo-1,2,3,5,6,7-hexahydro-4H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-one
-
3-[3-(1H-imidazol-1-yl)propyl]-2-thioxo-2,3,5,6,7,8,9,10-octahydrocycloocta[4,5]thieno[2,3-d]pyrimidin-4(1H)-one
-
3-[3-(1H-imidazol-1-yl)propyl]-2-thioxo-2,3,5,6,7,8-hexahydro[1]benzothieno[2,3-d]pyrimidin-4(1H)-one
-
3-[3-(1H-imidazol-1-yl)propyl]-2-thioxoimidazolidin-4-one
-
3-[3-(5-methyl-1H-imidazol-1-yl)propyl]-2-sulfanylidene-2,3,5,6,7,8-hexahydro[1]benzothieno[2,3-d]pyrimidin-4(1H)-one
-
3-[3-(5-methyl-1H-imidazol-1-yl)propyl]-2-sulfanylidene-2,3-dihydroquinazolin-4(1H)-one
-
3-[3-(5-methyl-1H-imidazol-1-yl)propyl]-2-thioxo-2,3,5,6,7,8,9,10-octahydrocycloocta[4,5]-thieno[2,3-d]pyrimidin-4(1H)-one
-
3-[3-(5-methyl-1H-imidazol-1-yl)propyl]-2-thioxo-2,3,5,6,7,8-hexahydro[1]benzothieno[2,3-d]pyrimidin-4(1H)-one
-
3-[4-(1H-imidazol-1-yl)butoxy]benzaldehyde
-
4'-fluoro-N-[3-(4-methyl-1H-imidazol-1-yl)propyl][1,1'-biphenyl]-2-amine
-
4-(2-imidazol-1-yl-ethoxy)-benzoic acid
-
4-imidazole-carboxaldehyde
-
4-phenyl-1,2,4-triazoleine-3,5-dione
-
0.14 mM, 22% inhibition
4-[2-(1H-imidazol-1-yl)ethoxy]benzaldehyde
-
4-[2-[4-([1-[(3-aminophenyl)methyl]-1H-imidazol-2-yl]methyl)-1H-imidazol-1-yl]ethoxy]benzaldehyde
-
5,6-dimethoxy-N-(3-(5-methyl-1H-imidazol-1-yl)propyl)-1Hbenzo[d]imidazol-2-amine
-
5,6-dimethoxy-N-[3-(5-methyl-1H-imidazol-1-yl)propyl]-1,3-benzothiazol-2-amine
-
5,6-dimethoxy-N-[3-(5-methyl-1H-imidazol-1-yl)propyl]-1H-benzimidazol-2-amine
-
5,7-dihydroxy-2-(3-methylphenyl)-4H-1-benzopyran-4-one
-
5,7-dihydroxy-2-(3-methylthiophen-2-yl)-4H-chromen-4-one
91.6% inhibition at 0.1 mM
5,7-dihydroxy-2-(5-methylthiophen-2-yl)-4H-1-benzopyran-4-one
-
5,7-dihydroxy-2-(5-methylthiophen-2-yl)-4H-chromen-4-one
92.4% inhibition at 0.1 mM
5,7-dihydroxy-2-(m-tolyl)-4H-chromen-4-one
93.0% inhibition at 0.1 mM
5,7-dihydroxy-2-(thiophen-2-yl)-4H-1-benzopyran-4-one
-
5,7-dihydroxy-2-(thiophen-2-yl)-4H-chromen-4-one
92.6% inhibition at 0.1 mM
5-(5-[[(3,4-dimethoxyphenyl)sulfanyl]methyl]-1,3,4-oxadiazol-2-yl)-1H-benzimidazole
-
5-(5-[[(pyridin-4-yl)methyl]sulfanyl]-1,3,4-oxadiazol-2-yl)-1H-benzimidazole
-
5-(methylthio)-1-H-tetrazole
-
0.14 mM, 11% inhibition
5-amino-3H-imidazole-4-carboxylic acid amide
-
5-hydroxymethyl-4-methyl-imidazole
-
5-[5-(2-phenylethyl)-1,3,4-oxadiazol-2-yl]-1H-benzimidazole
-
6-benzyl-2,3-dihydro-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)-2-thioxothieno[2,3-d]pyrimidin-4(1H)-one
-
7-hydroxy-2-(2-(trifluoromethyl)phenyl)-4H-chromen-4-one
70.8% inhibition at 0.1 mM
7-hydroxy-2-(2-methoxyphenyl)-4H-chromen-4-one
54.5% inhibition at 0.1 mM
7-hydroxy-2-(3,4,5-trimethoxyphenyl)-4H-chromen-4-one
68.7% inhibition at 0.1 mM
7-hydroxy-2-(4-(methylthio)phenyl)-4H-chromen-4-one
75.8% inhibition at 0.1 mM
7-hydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
71.8% inhibition at 0.1 mM
7-hydroxy-2-(4-methoxyphenyl)-4H-chromen-4-one
75.2% inhibition at 0.1 mM
7-hydroxy-2-(5-methylfuran-2-yl)-4H-chromen-4-one
78.9% inhibition at 0.1 mM
7-hydroxy-2-(pyridin-2-yl)-4H-chromen-4-one
62.4% inhibition at 0.1 mM
7-hydroxy-2-(pyridin-3-yl)-4H-chromen-4-one
65.2% inhibition at 0.1 mM
7-hydroxy-2-(pyridin-4-yl)-4H-chromen-4-one
87.1% inhibition at 0.1 mM
diethyl dicarbonate
-
rapid inactivation by modification of three essential His residues, at neutral pH, partial reactivation with hydroxylamine
dipicolinic acid
inactivated enzyme can be fully restored by addition of Zn2+ in the presence of equimolar concentrations of EDTA, little reactivation by Co2+ and Mn2+
EFRH-NH2
-
competitive inhibitor with L-glutaminyl-7-amido-4-methylcumarin as substrate
EFRHHDSGYE-NH2
-
competitive inhibitor with L-glutaminyl-7-amido-4-methylcumarin as substrate
ethyl-1H-tetrazole-4-acetate
-
0.14 mM, 9% inhibition
H-Gln-7-amido-4-methylcoumarin
-
substrate inhibition
H-Gln-beta-naphthylamide
-
substrate inhibition
imidazol-4-carbonic acid methylester
-
L-glutaminyl-7-amido-4-methylcoumarin
-
substrate inhibition
L-glutaminyl-beta-naphthylamide
-
substrate inhibition
methyl N-[(2S)-1-hydroxy-2-[[3-(5-methyl-1H-imidazol-1-yl)propyl]amino]-3-phenylpropyl]-L-alaninate
-
N''-cyano-N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-[3-(5-methyl-1H-imidazol-1-yl)propyl]guanidine
-
N''-cyano-N-(5-methyl-1H-imidazol-1-yl)-N'-(3,4,5-trimethoxyphenyl)guanidine
-
N''-cyano-N-methyl-N'-[3-(4-methyl-1H-imidazol-1-yl)propyl]guanidine
-
N''-cyano-N-methyl-N'-[3-(5-methyl-1H-imidazol-1-yl)propyl]guanidine
-
N-((E)-4-(3-(4-(2-aminoethyl)piperazin-1-yl)-3-oxoprop-1-en-1-yl)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-((E)-4-(3-oxo-3-(piperazin-1-yl)prop-1-en-1-yl)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-((E)-4-(3-oxo-3-(piperidin-4-ylamino)prop-1-en-1-yl)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(1-(3-(1H-imidazol-1-yl)propylamino)-2-nitrovinyl)-2,3-dihydrobenzo[b][1,4]-dioxin-6-amine
-
N-(1-(3-(1H-imidazol-1-yl)propylamino)-2-nitrovinyl)-3,4-dimethoxy-benzenamine
-
N-(1-(3-(1H-imidazol-1-yl)propylamino)-2-nitrovinyl)-4-(trifluoromethyl)-benzenamine
-
N-(1-(3-(1H-imidazol-1-yl)propylamino)-2-nitrovinyl)-4-chlorobenzenamine
-
N-(1-(3-(1H-imidazol-1-yl)propylamino)-2-nitrovinyl)-4-methoxybenzenamine
-
N-(1-(3-(1H-imidazol-1-yl)propylamino)-2-nitrovinyl)benzenamine
-
N-(1-(3-(1H-imidazol-1-yl)propylamino)-2-nitrovinyl)naphthalen-1-amine
-
N-(1-(3-(4-methyl-1H-imidazol-1-yl)propylamino)-2-nitrovinyl)-2,3-dihydrobenzo[b][1,4]-dioxin-6-amine
-
N-(1-(3-(5-methyl-1H-imidazol-1-yl)propylamino)-2-nitrovinyl)-2,3-dihydrobenzo[b][1,4]-dioxin-6-amine
-
N-(1-(3-(5-methyl-1H-imidazol-1-yl)propylamino)-2-nitrovinyl)-4-(trifluoromethyl)benzenamine
-
N-(1-(3-(5-methyl-1H-imidazol-1-yl)propylamino)-2-nitrovinyl)-4-chloro-benzenamine
-
N-(1-(3-(5-methyl-1H-imidazol-1-yl)propylamino)-2-nitrovinyl)cyclohexanamine
-
N-(1-(3-(5-methyl-1H-imidazol-1-yl)propylamino)-2-nitrovinyl)naphthalen-1-amine
-
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-[3-(5-methyl-1H-imidazol-1-yl)propyl]thiourea
-
N-(3,4-dimethoxyphenyl)-4-[2-(5-methyl-1H-imidazol-1-yl)ethyl]-1,3-thiazol-2-amine
-
N-(3,4-dimethoxyphenyl)-5-[2-(5-methyl-1H-imidazol-1-yl)ethyl]-1,3,4-oxadiazol-2-amine
-
N-(3,4-dimethoxyphenyl)-N'-(4-methyl-1H-imidazol-1-yl)thiourea
-
N-(3,4-dimethoxyphenyl)-N'-(5-methyl-1H-imidazol-1-yl)thiourea
-
N-(3,4-dimethoxyphenyl)-N'-1H-imidazol-1-ylthiourea
-
N-(3,4-dimethoxyphenyl)-N'-[3-(1H-imidazol-1-yl)-2-methylpropyl]thiourea
-
N-(3,4-dimethoxyphenyl)-N'-[3-(1H-imidazol-1-yl)propyl]thiourea
N-(3,4-dimethoxyphenyl)-N'-[3-(5-methyl-1H-imidazol-1-yl)propyl]thiourea
N-(3-(1H-imidazol-1-yl)propyl)-N-cyclohexyl-2-nitroethene-1,1-diamine
-
N-(3-(1H-imidazol-1-yl)propyl)-N-methyl-2-nitroethene-1,1-diamine
-
N-(3-(2-(2-aminopyridin-4-yl)ethoxy)-4-methoxyphenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(3-(2-aminoethoxy)-4-methoxyphenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(3-(3-(2-aminopyridin-4-yl)propoxy)-4-methoxyphenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(3-(3-aminopropoxy)-4-methoxyphenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(3-(4-(2-aminopyridin-4-yl)butoxy)-4-methoxyphenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(3-(4-(dimethylamino)butoxy)-4-methoxyphenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(3-(4-aminobutoxy)-4-methoxyphenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(3-methoxy-4-[[4-(piperidin-4-yl)phenyl]methoxy]phenyl)-N'-[3-(5-methyl-1H-imidazol-1-yl)propyl]thiourea
-
N-(4'-fluoro[1,1'-biphenyl]-2-yl)-4-methyl-1H-imidazol-1-amine
-
N-(4-((1-(2-aminoethyl)piperidin-4-yl)carbamoyl)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(4-(2-(((2-aminopyridin-4-yl)methyl)amino)-2-oxoethoxy)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(4-(2-((1-(2-aminoethyl)piperidin-4-yl)amino)-2-oxoethoxy)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(4-(2-(piperazin-1-yl)ethoxy)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(4-(2-oxo-2-(piperazin-1-yl)ethoxy)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(4-(2-oxo-2-(piperidin-4-ylamino)ethoxy)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(4-(4-(2-aminopyridin-4-yl)butoxy)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(4-chlorophenyl)-N'-[2-(1H-imidazol-1-yl)propyl]-2-thioxoimidazolidin-4-one
-
N-(4-chlorophenyl)-N'-[3-(1H-imidazol-1-yl)propyl]thiourea
-
N-(4-methoxy-3-(2-(1-methylpiperidin-4-yl)ethoxy)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(4-methoxy-3-(2-(piperazin-1-yl)ethoxy)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(4-methoxy-3-(2-(piperidin-4-yl)ethoxy)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(4-methoxy-3-(3-(methylamino)propoxy)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(4-methoxy-3-(3-(piperazin-1-yl)propoxy)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(4-methoxy-3-(3-(piperidin-4-yl)propoxy)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(4-methoxy-3-(4-(methylamino)butoxy)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(4-methoxy-3-(4-(piperazin-1-yl)butoxy)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(4-methoxy-3-(4-(piperidin-4-yl)butoxy)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(4-methoxy-3-(4-(pyrimidin-2-ylamino)butoxy)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(4-[(1E)-3-[4-(2-aminoethyl)piperazin-1-yl]-3-oxoprop-1-en-1-yl]phenyl)-N'-(5-methyl-1H-imidazol-1-yl)thiourea
-
N-(E)-(4-(3-(4-(2-aminoethyl)piperazin-1-yl)-3-oxoprop-1-en-1-yl)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(trimethylsilyl)-imidazole
-
N-[3-(1H-imidazol-1-yl)propyl]-5-methoxy-1,3-benzothiazol-2-amine
-
-
N-[3-(1H-imidazol-1-yl)propyl]-6-methoxy-1,3-benzothiazol-2-amine
-
-
N-[3-(1H-imidazol-1-yl)propyl]-N'-phenylthiourea
-
N-[3-(4-aminobutoxy)-4-methoxyphenyl]-N'-[3-(2-methyl-1H-imidazol-1-yl)propyl]thiourea
-
N-[3-methoxy-4-[(piperidin-4-yl)methoxy]phenyl]-N'-(5-methyl-1H-imidazol-1-yl)thiourea
-
N-[4-(2-aminoethoxy)-3-methoxyphenyl]-N'-(5-methyl-1H-imidazol-1-yl)thiourea
-
N-[4-(3-aminopropoxy)-3-methoxyphenyl]-N'-(5-methyl-1H-imidazol-1-yl)thiourea
-
N-[4-(4-aminobutoxy)-3-methoxyphenyl]-N'-(5-methyl-1H-imidazol-1-yl)thiourea
-
N-[4-[3-(2-aminopyridin-4-yl)propoxy]-3-methoxyphenyl]-N'-(5-methyl-1H-imidazol-1-yl)thiourea
-
N2-[(2S)-1-hydroxy-2-[[3-(5-methyl-1H-imidazol-1-yl)propyl]amino]-3-phenylpropyl]-L-alaninamide
-
nitron
-
0.14 mM, 39% inhibition
oxalic acid diimidazolidide
-
PQ529
can efficiently inhibit the activity of both glutaminyl cyclase isozymes QC and isoQC. Treatment with PQ529 for 48 h significantly blocks the binding of CC2C6 to the cell surface in a dosage-dependent manner in wild-type, but not in isoQC-deficient cells
SEN-177
the triazole based inhibitor, SEN177 coordinates with the catalytically important Zn2+ ion of sQC and has made several hydrophobic interactions with active site residues such as W207, F325, and W329
1,10-phenanthroline
inactivated enzyme can be fully restored by addition of Zn2+ in the presence of equimolar concentrations of EDTA, little reactivation by Co2+ and Mn2+
1,2-di-O-palmitoyl-3-O-(6'-deoxy-6'-sulfo-D-glycopyranosyl)-glycerol
-
1,2-di-O-palmitoyl-3-O-(6'-deoxy-6'-sulfo-D-glycopyranosyl)-glycerol
-
1-(3,4-dimethoxyphenyl)-3-[3-(1H-imidazol-1-yl)propyl]thiourea
-
i.e. P150/03, complete inhibition at 0.01 mM
1-(3,4-dimethoxyphenyl)-3-[3-(1H-imidazol-1-yl)propyl]thiourea
-
-
1-Benzylimidazole
-
1-Benzylimidazole
-
0.14 mM, 58% inhibition
1-Benzylimidazole
weak inhibition; weak inhibition
1-O-linolyl-2-O-palmitoyl-3-O-(6'-deoxy-6'-sulfo-D-glucopyranosyl)-glycerol
-
1-O-linolyl-2-O-palmitoyl-3-O-(6'-deoxy-6'-sulfo-D-glucopyranosyl)-glycerol
-
1-O-palmitoyl-2-O-linolenyl-3-O-(6'-deoxy-6'-sulfo-D-glucopyranosyl)-glycerol
-
1-O-palmitoyl-2-O-linolenyl-3-O-(6'-deoxy-6'-sulfo-D-glucopyranosyl)-glycerol
-
1-vinylimidazole
-
1-vinylimidazole
weak inhibition; weak inhibition
apigenin
75.2% inhibition at 0.1 mM
benzimidazole
-
-
benzimidazole
-
competitive
benzylimidazole
-
-
benzylimidazole
-
competitive
cysteamine
-
-
imidazole
-
N-(3,4-dimethoxyphenyl)-N'-[3-(1H-imidazol-1-yl)propyl]thiourea
-
N-(3,4-dimethoxyphenyl)-N'-[3-(1H-imidazol-1-yl)propyl]thiourea
-
N-(3,4-dimethoxyphenyl)-N'-[3-(5-methyl-1H-imidazol-1-yl)propyl]thiourea
-
N-(3,4-dimethoxyphenyl)-N'-[3-(5-methyl-1H-imidazol-1-yl)propyl]thiourea
-
N-(3,4-dimethoxyphenyl)-N'-[3-(5-methyl-1H-imidazol-1-yl)propyl]thiourea
-
N-omega-acetylhistamine
-
N-omega-acetylhistamine
-
-
N-omega-acetylhistamine
-
0.14 mM, 33% inhibition
N-omega-acetylhistamine
-
-
N-omega-acetylhistamine
weak inhibition; weak inhibition
Nomega-acetylhistamine
-
PBD150
-
-
PBD150
highly potent inhibitor
PQ912
-
SEN177
i.e. 6''-fluoro-4-(4-methyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2',3',3'']terpyridine, binding structure with Golgi-resident hQC; i.e. 6''-fluoro-4-(4-methyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2',3',3'']terpyridine, binding structure with secretory hQC
additional information
phenol-40 (R1-), C5-OH (R2-) and C7-OH (R3-) modified apigenin derivatives are synthesized and evaluated as human QC (hQC) inhibitors, structure-function analysis, molecular docking, overview. No inhibition by 7-methoxy-2-(3-methylthiophen-2-yl)-4H-chromen-4-one, 7-methoxy-2-(4-methoxyphenyl)-4H-chromen-4-one, 7-methoxy-2-(2-methoxyphenyl)-4H-chromen-4-one, 2-(3,4-dimethoxyphenyl)-7-methoxy-4H-chromen-4-one, 7-methoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromen-4-one, 2-(4-fluorophenyl)-7-methoxy-4H-chromen-4-one, 2-(3-fluorophenyl)-7-methoxy-4H-chromen-4-one, 7-methoxy-2-(2-(trifluoromethyl)phenyl)-4H-chromen-4-one, 7-methoxy-2-(pyridin-3-yl)-4H-chromen-4-one, 2-(furan-2-yl)-7-methoxy-4H-chromen-4-one, and 2-(furan-3-yl)-7-methoxy-4H-chromen-4-one
-
additional information
-
phenol-40 (R1-), C5-OH (R2-) and C7-OH (R3-) modified apigenin derivatives are synthesized and evaluated as human QC (hQC) inhibitors, structure-function analysis, molecular docking, overview. No inhibition by 7-methoxy-2-(3-methylthiophen-2-yl)-4H-chromen-4-one, 7-methoxy-2-(4-methoxyphenyl)-4H-chromen-4-one, 7-methoxy-2-(2-methoxyphenyl)-4H-chromen-4-one, 2-(3,4-dimethoxyphenyl)-7-methoxy-4H-chromen-4-one, 7-methoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromen-4-one, 2-(4-fluorophenyl)-7-methoxy-4H-chromen-4-one, 2-(3-fluorophenyl)-7-methoxy-4H-chromen-4-one, 7-methoxy-2-(2-(trifluoromethyl)phenyl)-4H-chromen-4-one, 7-methoxy-2-(pyridin-3-yl)-4H-chromen-4-one, 2-(furan-2-yl)-7-methoxy-4H-chromen-4-one, and 2-(furan-3-yl)-7-methoxy-4H-chromen-4-one
-
additional information
structure-activity relationship analysis of Phe-Arg mimetic region of human glutaminyl cyclase inhibitors. Developed of QC inhibitors that contain 3-aminoalkyloxy-4-methoxyphenyl and 4-aminoalkyloxyphenyl groups to replace the previously developed pharmacophore, overview. In vivo activity of the compounds is analyzed using HT-22 cells, an immortalized hippocampal neuronal cell line
-
additional information
-
structure-activity relationship analysis of Phe-Arg mimetic region of human glutaminyl cyclase inhibitors. Developed of QC inhibitors that contain 3-aminoalkyloxy-4-methoxyphenyl and 4-aminoalkyloxyphenyl groups to replace the previously developed pharmacophore, overview. In vivo activity of the compounds is analyzed using HT-22 cells, an immortalized hippocampal neuronal cell line
-
additional information
development of small molecule inhibitors of glutaminyl cyclase and isoglutaminyl cyclase for Alzheimers disease, overview; development of small molecule inhibitors of glutaminyl cyclase and isoglutaminyl cyclase for Alzheimers disease, overview. Weak inhibition by imidazole derivatives
-
additional information
development of small molecule inhibitors of glutaminyl cyclase and isoglutaminyl cyclase for Alzheimers disease, overview; development of small molecule inhibitors of glutaminyl cyclase and isoglutaminyl cyclase for Alzheimers disease, overview. Weak inhibition by imidazole derivatives
-
additional information
crystal structures of weak binding inhibitors of human QC isozymes, all share the imidazole ring as the Zn(II) binding moiety, overview; crystal structures of weak binding inhibitors of human QC isozymes, share the imidazole ring as the Zn(II) binding moiety, overview
-
additional information
crystal structures of weak binding inhibitors of human QC isozymes, all share the imidazole ring as the Zn(II) binding moiety, overview; crystal structures of weak binding inhibitors of human QC isozymes, share the imidazole ring as the Zn(II) binding moiety, overview
-
additional information
-
crystal structures of weak binding inhibitors of human QC isozymes, all share the imidazole ring as the Zn(II) binding moiety, overview; crystal structures of weak binding inhibitors of human QC isozymes, share the imidazole ring as the Zn(II) binding moiety, overview
-
additional information
natural products from microalgae, such as Scenedesmus rubescens strain SAG 5.95, Scenedesmus producto-capitatus strain SAG 21.81, Scenedesmus accuminatus strain SAG 38.81, Scenedesmus pectinatus strain SAG 2003, Tetradesmus wisconsinensis strain SAG 3.99, and Eustigmatos magnus strain SAG 36.89, show potential against Alzheimers disease, sulfolipids are potent glutaminyl cyclase inhibitors. Mass spectrometric identification and analysis (high resolution ESI-FTIC-MS and UPLC-MS, UPLC/ESI-MSn measurements). The sulfolipids share common, necessary substructures with pharmacophore characteristics of known QC inhibitors
-
additional information
structure-function analysis of enzyme inhibitors, overview; structure-function analysis of enzyme inhibitors, overview. Natural products and their derivatives belonging to the sulfolipid family and isolated from methanol extracts of different algae species (such as Scenedesmus rubescens, Scenedesmus producto-capitatus, Scenedesmus accuminatus, Scenedesmus pectinatus, Tetradesmus wisconsinensis, and Eustigmatos magnusa) act as inhibitors of sQC. Synthesis and evaluation of benzimidazole based inhibitors, overview
-
additional information
structure-function analysis of enzyme inhibitors, overview; structure-function analysis of enzyme inhibitors, overview. Natural products and their derivatives belonging to the sulfolipid family and isolated from methanol extracts of different algae species (such as Scenedesmus rubescens, Scenedesmus producto-capitatus, Scenedesmus accuminatus, Scenedesmus pectinatus, Tetradesmus wisconsinensis, and Eustigmatos magnusa) act as inhibitors of sQC. Synthesis and evaluation of benzimidazole based inhibitors, overview
-
additional information
-
structure-function analysis of enzyme inhibitors, overview; structure-function analysis of enzyme inhibitors, overview. Natural products and their derivatives belonging to the sulfolipid family and isolated from methanol extracts of different algae species (such as Scenedesmus rubescens, Scenedesmus producto-capitatus, Scenedesmus accuminatus, Scenedesmus pectinatus, Tetradesmus wisconsinensis, and Eustigmatos magnusa) act as inhibitors of sQC. Synthesis and evaluation of benzimidazole based inhibitors, overview
-
additional information
in vitro and in silico determination of glutaminyl cyclase inhibitors, heterocyclic and peptidomimetic derivatives are synthesized and are able to inhibit the hQC enzyme, overview. The binding mechanism at the atomic level is estimated using molecular docking, free energy perturbation, and quantum chemical calculation methods. The predicted log(BBB) and human intestinal absorption values indicated that these compounds are able to permeate the blood-brain barrier and be well-absorbed through the gastrointestinal tract. Molecular docking study and atomistic molecular dynamics simulations, overview
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Alzheimer Disease
2D- and 3D-QSAR Modeling of Imidazole-Based Glutaminyl Cyclase Inhibitors.
Alzheimer Disease
An overview of glutaminyl cyclase inhibitors for Alzheimer's disease.
Alzheimer Disease
Discovery of highly potent human glutaminyl cyclase (QC) inhibitors as anti-Alzheimer's agents by the combination of pharmacophore-based and structure-based design.
Alzheimer Disease
Discovery of Potent Human Glutaminyl Cyclase Inhibitors as Anti-Alzheimer's Agents Based on Rational Design.
Alzheimer Disease
Distinct glutaminyl cyclase expression in Edinger-Westphal nucleus, locus coeruleus and nucleus basalis Meynert contributes to pGlu-Abeta pathology in Alzheimer's disease.
Alzheimer Disease
Disturbed ca(2+) homeostasis increases glutaminyl cyclase expression; connecting two early pathogenic events in Alzheimer's disease in vitro.
Alzheimer Disease
Exploring the binding mode of PQ912 against secretory glutaminyl cyclase through systematic exploitation of conformational ensembles.
Alzheimer Disease
Glutaminyl cyclase activity correlates with levels of A? peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer's disease patients.
Alzheimer Disease
Glutaminyl cyclase in human cortex: correlation with (pGlu)-amyloid-? load and cognitive decline in Alzheimer's disease.
Alzheimer Disease
Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology.
Alzheimer Disease
Glutaminyl cyclase inhibitor contributes to the regulation of HSP70, HSP90, actin, and ribosome on gene and protein levels in vitro.
Alzheimer Disease
Glutaminyl cyclase inhibitor exhibits anti-inflammatory effects in both AD and LPS-induced inflammatory model mice.
Alzheimer Disease
Human glutaminyl cyclase: Structure, function, inhibitors and involvement in Alzheimer's disease.
Alzheimer Disease
Hydrazides Are Potent Transition-State Analogues for Glutaminyl Cyclase Implicated in the Pathogenesis of Alzheimer's Disease.
Alzheimer Disease
Hypothesis: glutaminyl cyclase inhibitors decrease risks of Alzheimer's disease and related dementias.
Alzheimer Disease
Identification of thyrotropin-releasing hormone as hippocampal glutaminyl cyclase substrate in neurons and reactive astrocytes.
Alzheimer Disease
Identifying hQC Inhibitors of Alzheimer's Disease by Effective Customized Pharmacophore-Based Virtual Screening, Molecular Dynamic Simulation, and Binding Free Energy Analysis.
Alzheimer Disease
In silico exploration of the fingerprints triggering modulation of glutaminyl cyclase inhibition for the treatment of Alzheimer's disease using SMILES based attributes in Monte Carlo optimization.
Alzheimer Disease
Increased glutaminyl cyclase activity in brains of Alzheimer's disease individuals.
Alzheimer Disease
Increased glutaminyl cyclase expression in peripheral blood of Alzheimer's disease patients.
Alzheimer Disease
Inhibition of glutaminyl cyclase ameliorates amyloid pathology in an animal model of Alzheimer's disease via the modulation of ?-secretase activity.
Alzheimer Disease
Inhibitors for Human Glutaminyl Cyclase by Structure Based Design and Bioisosteric Replacement.
Alzheimer Disease
Inhibitory effect of flavonoids on human glutaminyl cyclase.
Alzheimer Disease
Isoglutaminyl cyclase contributes to CCL2-driven neuroinflammation in Alzheimer's disease.
Alzheimer Disease
Monogalactosyldiacylglycerol and Sulfolipid Synthesis in Microalgae.
Alzheimer Disease
Natural Products from Microalgae with Potential against Alzheimer's Disease: Sulfolipids Are Potent Glutaminyl Cyclase Inhibitors.
Alzheimer Disease
Potent human glutaminyl cyclase inhibitors as potential anti-Alzheimer's agents: Structure-activity relationship study of Arg-mimetic region.
Alzheimer Disease
PYROGLUTAMATE FORMATION AT THE N-TERMINI OF ABRI MOLECULES IN FAMILIAL BRITISH DEMENTIA IS NOT RESTRICTED TO THE CENTRAL NERVOUS SYSTEM.
Alzheimer Disease
Repurposing FDA-Approved Compounds for the Discovery of Glutaminyl Cyclase Inhibitors as Drugs Against Alzheimer's Disease.
Alzheimer Disease
Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study.
Alzheimer Disease
Structure-activity relationships of benzimidazole-based glutaminyl cyclase inhibitors featuring a heteroaryl scaffold.
Alzheimer Disease
Structures of Human Golgi-resident Glutaminyl Cyclase and Its Complexes with Inhibitors Reveal a Large Loop Movement upon Inhibitor Binding.
Alzheimer Disease
Synthesis and Evaluation of Diphenyl Conjugated Imidazole Derivatives as Potential Glutaminyl Cyclase Inhibitors for Treatment of Alzheimer's Disease.
Alzheimer Disease
Synthesis and evaluation of [(11)C]PBD150, a radiolabeled glutaminyl cyclase inhibitor for the potential detection of Alzheimer's disease prior to amyloid ? aggregation.
Alzheimer Disease
The soluble Y115E-Y117E variant of human glutaminyl cyclase is a valid target for X-ray and NMR screening of inhibitors against Alzheimer disease.
Alzheimer Disease
The structure of the human glutaminyl cyclase-SEN177 complex indicates routes for developing new potent inhibitors as possible agents for the treatment of neurological disorders.
Amyloidosis
Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology.
Amyloidosis
PYROGLUTAMATE FORMATION AT THE N-TERMINI OF ABRI MOLECULES IN FAMILIAL BRITISH DEMENTIA IS NOT RESTRICTED TO THE CENTRAL NERVOUS SYSTEM.
Anemia
Luteolin promotes macrophage-mediated phagocytosis by inhibiting CD47 pyroglutamation.
Arthritis, Rheumatoid
Expression of human and Porphyromonas gingivalis glutaminyl cyclases in periodontitis and rheumatoid arthritis-A pilot study.
Brain Ischemia
Alterations in mRNA expression of BACE1, cathepsin B, and glutaminyl cyclase in mice ischemic brain.
Chronic Periodontitis
Expression of human and Porphyromonas gingivalis glutaminyl cyclases in periodontitis and rheumatoid arthritis-A pilot study.
Dementia
Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology.
Dementia
Hypothesis: glutaminyl cyclase inhibitors decrease risks of Alzheimer's disease and related dementias.
Dementia
Increased glutaminyl cyclase expression in peripheral blood of Alzheimer's disease patients.
Goiter
Role of glutaminyl cyclases in thyroid carcinomas.
Hypogonadism
Glutaminyl cyclase (QC) knock out mice show mild hypothyreodism but absence of hypogonadism: implications for enzyme function and drug development.
Insulinoma
Isolation, catalytic properties, and competitive inhibitors of the zinc-dependent murine glutaminyl cyclase.
Melanoma
Microarray evidence of glutaminyl cyclase gene expression in melanoma: implications for tumor antigen specific immunotherapy.
Neoplasms
Enhancement of epidermal growth factor receptor antibody tumor immunotherapy by glutaminyl cyclase inhibition to interfere with CD47/signal regulatory protein alpha interactions.
Neoplasms
Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRP? axis and a target for cancer immunotherapy.
Neoplasms
Microarray evidence of glutaminyl cyclase gene expression in melanoma: implications for tumor antigen specific immunotherapy.
Neoplasms
Proteomic Characterization of Two Medically Important Malaysian Snake Venoms, Calloselasma rhodostoma (Malayan Pit Viper) and Ophiophagus hannah (King Cobra).
Neurodegenerative Diseases
2D- and 3D-QSAR Modeling of Imidazole-Based Glutaminyl Cyclase Inhibitors.
Neurodegenerative Diseases
The soluble Y115E-Y117E variant of human glutaminyl cyclase is a valid target for X-ray and NMR screening of inhibitors against Alzheimer disease.
Neuroinflammatory Diseases
Isoglutaminyl cyclase contributes to CCL2-driven neuroinflammation in Alzheimer's disease.
Obesity
A nonsense loss-of-function mutation in PCSK1 contributes to dominantly inherited human obesity.
Obesity
What model organisms and interactomics can reveal about the genetics of human obesity.
Overweight
Replication of Established Common Genetic Variants for Adult BMI and Childhood Obesity in Greek Adolescents: The TEENAGE Study.
Pediatric Obesity
Role of BMI-Associated Loci Identified in GWAS Meta-Analyses in the Context of Common Childhood Obesity in European Americans.
Periodontitis
Expression of human and Porphyromonas gingivalis glutaminyl cyclases in periodontitis and rheumatoid arthritis-A pilot study.
Pheochromocytoma
Identification of potential gene markers and insights into the pathophysiology of pheochromocytoma malignancy.
Synucleinopathies
A glutaminyl cyclase-catalyzed ?-synuclein modification identified in human synucleinopathies.
Thyroid Neoplasms
Role of glutaminyl cyclases in thyroid carcinomas.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
6
EFRH-NH2
-
at pH 6.5, 10times higher compared to KM-value of Gln substrate
0.087 - 0.155
Gln(3)-amyloid-beta peptide 3-11 amide
-
0.162
Gln(3)-amyloid-beta peptide 3-21 amide
-
pH 6.0, 30°C, 1% DMSO
-
0.089
Gln(3)-amyloid-beta peptide 3-40 amide
-
pH 6.0, 30°C, 1% DMSO
-
0.058 - 1.1
Gln-2-naphthylamide
0.054
Gln-7-amido-4-methylcoumarin
-
pH 8.0, 30°C
0.065
Gln-Ala-Ala-Ala-Ala-NH2
-
pH 8.0, 30°C
0.087
Gln-Ala-Ala-NH2
-
pH 8.0, 30°Cl
0.079
Gln-Ala-Ala-Ser-Ala-Ala-NH2
-
pH 8.0, 30°C
0.091 - 0.143
Gln-Arg-Gly-Ile-NH2
0.055
Gln-Arg-Tyr-Phe-NH2
-
pH 8.0, 30°C
0.172
Gln-Asn-Gly-Ile-NH2
-
pH 8.0, 30°C
0.07
Gln-beta-naphthylamide
-
pH 8.0, 30°C
0.148
Gln-Gln-OH
-
30°C, recombinant enzyme, expressed in Pichia pastoris
0.041
Gln-Gln-Tyr-Phe-NH2
-
pH 8.0, 30°C
0.077
Gln-Glu-Ala-Ala-NH2
-
pH 8.0, 30°C
0.039
Gln-Glu-Ala-Phe-NH2
-
pH 8.0, 30°C
0.055 - 0.061
Gln-Glu-Asp-Leu-NH2
0.069
Gln-Glu-Tyr-Ala-NH2
-
pH 8.0, 30°C
0.079
Gln-Glu-Tyr-NH2
-
pH 8.0, 30°C
0.047
Gln-Glu-Tyr-Phe-NH2
-
pH 8.0, 30°C
0.09
Gln-His-Pro-NH2
-
30°C, recombinant enzyme, expressed in Pichia pastoris
0.068
Gln-His-Tyr-Phe-NH2
-
pH 8.0, 30°C
0.034 - 0.054
Gln-Lys-Arg-Leu-NH2
0.1
Gln-Phe-Ala
-
protein version: shortened N-terminus, I73N/C369A, His-tagged, pH 8.0, 30°C, similar value with other protein versions
0.069
Gln-Phe-Ala-NH2
-
pH 8.0, 30°C
18.89
Gln-Pro-Tyr-Phe-NH2
-
pH 8.0, 30°C
0.055
Gln-Ser-Tyr-Phe-NH2
-
pH 8.0, 30°C
1.235 - 6.7
Gln-tert-butyl ester
0.05 - 0.056
Gln-Trp-Ala-NH2
0.211
Gln-Tyr
-
pH 8.0, 30°C
0.101 - 0.153
Gln-Tyr-Ala-OH
0.196
Gln-Val
-
pH 8.0, 30°C
0.019
glucagon(3-29)
-
pH 6.0, 30°C, 1% DMSO
-
0.017
H-Gln-7-amido-4-methylcoumarin
-
pH 8.0, 30°C
0.036
H-Gln-beta-naphthylamide
-
pH 8.0, 30°C
0.115
H-Gln-Gln-OH
-
pH 8.0, 30°C
0.705
H-Gln-Glu-OH
-
pH 8.0, 30°C
0.424
H-Gln-Gly-OH
-
pH 8.0, 30°C
0.214
H-Gln-Gly-Pro-OH
-
pH 8.0, 30°C
0.06
L-glutaminyl-2-naphthylamide
-
30°C, recombinant enzyme, expressed in Pichia pastoris
0.051
L-glutaminyl-4-methylcoumarinylamide
-
30°C, recombinant enzyme, expressed in Pichia pastoris
0.03
L-glutaminyl-7-amido-4-methylcoumarin
-
protein version: shortened N-terminus, I73N/C369A, His-tagged, pH 8.0, 30°C, similar value with other protein versions
0.035
L-glutaminyl-beta-naphthylamide
-
protein version: shortened N-terminus, I73N/C369A, His-tagged, pH 8.0, 30°C, similar value with other protein versions
0.063
N1-naphthalen-2-yl-L-glutamamide
-
pH 8.0, 30°C, 0.5 M KCl
0.16
QEDL
-
protein version: shortened N-terminus, I73N/C369A, His-tagged, pH 8.0, 30°C, similar value with other protein versions
0.04
QEYF
-
protein version: shortened N-terminus, I73N/C369A, His-tagged, pH 8.0, 30°C, similar value with other protein versions
0.087
[Gln1]-fertilization promoting peptide
-
pH 8.0, 30°C
-
0.031
[Gln1]-gastrin
-
pH 8.0, 30°C
-
0.053
[Gln1]-gonadotropin releasing-hormone
-
pH 8.0, 30°C
-
0.037
[Gln1]-neurotensin
-
pH 8.0, 30°C
0.09
[Gln1]-thyrotropin releasing-hormone
-
pH 8.0, 30°C
-
additional information
additional information
-
0.087
Gln(3)-amyloid-beta peptide 3-11 amide
-
pH 6.0, 30°C, in absence of DMSO
-
0.155
Gln(3)-amyloid-beta peptide 3-11 amide
-
pH 6.0, 30°C, 1% DMSO
-
0.058
Gln-2-naphthylamide
-
pH 8.0, 25°C, wild-type enzyme
0.125
Gln-2-naphthylamide
-
pH 8.0, 25°C, mutant enzyme D248A
0.161
Gln-2-naphthylamide
-
pH 8.0, 25°C, mutant enzyme H319L
0.174
Gln-2-naphthylamide
-
pH 8.0, 25°C, mutant enzyme S160A
0.254
Gln-2-naphthylamide
-
pH 8.0, 25°C, mutant enzyme D305N
0.33
Gln-2-naphthylamide
-
pH 8.0, 25°C, mutant enzyme D248Q
0.431
Gln-2-naphthylamide
-
pH 8.0, 25°C, mutant enzyme D305E
0.615
Gln-2-naphthylamide
-
pH 8.0, 25°C, mutant enzyme S160G
0.736
Gln-2-naphthylamide
-
pH 8.0, 25°C, mutant enzyme E201D
1.1
Gln-2-naphthylamide
-
pH 8.0, 25°C, mutant enzyme D305A
0.232
Gln-Ala
-
pH 8.0, 30°C
0.357
Gln-Ala
-
pH 8.0, 30°C, 0.5 M KCl
0.091
Gln-Arg-Gly-Ile-NH2
-
pH 8.0, 30°C, 0.5 M KCl
0.143
Gln-Arg-Gly-Ile-NH2
-
pH 8.0, 30°C
0.11
Gln-Gln
-
protein version: shortened N-terminus, I73N/C369A, His-tagged, pH 8.0, 30°C, similar value with other protein versions
0.148
Gln-Gln
-
pH 8.0, 30°C
0.59
Gln-Gln
pH 8.0, mutant enzyme W207F
0.63
Gln-Gln
pH 8.0, wild-type enzyme
0.76
Gln-Gln
pH 8.0, mutant enzyme R54W
0.79
Gln-Gln
pH 7.0, wild-type enzyme
0.82
Gln-Gln
pH 8.0, mutant enzyme F146A
0.9
Gln-Gln
pH 7.5, wild-type enzyme
0.9
Gln-Gln
pH 8.5, wild-type enzyme
1.16
Gln-Gln
pH 8.0, mutant enzyme Q304L
1.47
Gln-Gln
pH 8.0, mutant enzyme K144A
1.77
Gln-Gln
pH 8.0, mutant enzyme W207L
2.06
Gln-Gln
pH 8.8, wild-type enzyme
4.67
Gln-Gln
pH 8.0, mutant enzyme F325A
12.62
Gln-Gln
pH 8.0, mutant enzyme E201D
29.53
Gln-Gln
pH 8.0, mutant enzyme W329A
0.359
Gln-Glu
-
pH 8.0, 30°C
0.607
Gln-Glu
-
pH 8.0, 30°C, 0.5 M KCl
0.61
Gln-Glu
-
protein version: shortened N-terminus, I73N/C369A, His-tagged, pH 8.0, 30°C, similar value with other protein versions
0.055
Gln-Glu-Asp-Leu-NH2
-
pH 8.0, 30°C
0.061
Gln-Glu-Asp-Leu-NH2
-
pH 8.0, 30°C, 0.5 M KCl
0.247
Gln-Gly
-
pH 8.0, 30°C
0.36
Gln-Gly
-
protein version: shortened N-terminus, I73N/C369A, His-tagged, pH 8.0, 30°C, similar value with other protein versions
0.13
Gln-Gly-Pro
-
pH 8.0, 30°C
0.23
Gln-Gly-Pro
-
protein version: shortened N-terminus, I73N/C369A, His-tagged, pH 8.0, 30°C, similar value with other protein versions
0.034
Gln-Lys-Arg-Leu-NH2
-
pH 8.0, 30°C, 0.5 M KCl
0.054
Gln-Lys-Arg-Leu-NH2
-
pH 8.0, 30°C
0.401
Gln-NH2
-
pH 8.0, 30°C, 0.5 M KCl
0.409
Gln-NH2
-
30°C, recombinant enzyme, expressed in Pichia pastoris
0.409
Gln-NH2
-
pH 8.0, 30°C
1.1
Gln-NH2
-
wild-type enzyme
4.3
Gln-NH2
-
mutant enzyme H307Q
4.9
Gln-NH2
-
mutant enzyme H319Q
1.235
Gln-tert-butyl ester
-
pH 8.0, 30°C
4.1
Gln-tert-butyl ester
-
-
6.7
Gln-tert-butyl ester
-
-
0.05
Gln-Trp-Ala-NH2
-
pH 8.0, 30°C
0.056
Gln-Trp-Ala-NH2
-
pH 8.0, 30°C, 0.5 M KCl
0.08
Gln-Tyr-Ala
-
protein version: shortened N-terminus, I73N/C369A, His-tagged, pH 8.0, 30°C, similar value with other protein versions
0.101
Gln-Tyr-Ala
-
pH 8.0, 30°C
0.101
Gln-Tyr-Ala-OH
-
30°C, recombinant enzyme, expressed in Pichia pastoris
0.153
Gln-Tyr-Ala-OH
-
37°C, recombinant enzyme, expressed in Pichia pastoris
additional information
additional information
Michaelis-Menten kinetics
-
additional information
additional information
Michaelis-Menten kinetics
-
additional information
additional information
-
Michaelis-Menten kinetics
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.00022
EFRH-NH2
-
at pH 6.5, 150000fold lower compared to Gln substrate
0.00042
EFRHHDSGYE-NH2
-
-
41.4 - 55
Gln(3)-amyloid-beta peptide 3-11 amide
-
62
Gln(3)-amyloid-beta peptide 3-21 amide
-
pH 6.0, 30°C, 1% DMSO
-
40
Gln(3)-amyloid-beta peptide 3-40 amide
-
pH 6.0, 30°C, 1% DMSO
-
0.0019 - 5.4
Gln-2-naphthylamide
5.3
Gln-7-amido-4-methylcoumarin
-
pH 8.0, 30°C
60.5
Gln-Ala-Ala-Ala-Ala-NH2
-
pH 8.0, 30°C
76.3
Gln-Ala-Ala-NH2
-
pH 8.0, 30°C
55.3
Gln-Ala-Ala-Ser-Ala-Ala-NH2
-
pH 8.0, 30°C
29.8 - 33.5
Gln-Arg-Gly-Ile-NH2
29.6
Gln-Arg-Tyr-Phe-NH2
-
pH 8.0, 30°C
56.6
Gln-Asn-Gly-Ile-NH2
-
pH 8.0, 30°C
20.6
Gln-beta-naphthylamide
-
pH 8.0, 30°C
12.8
Gln-Gln-OH
-
30°C, recombinant enzyme, expressed in Pichia pastoris
41.4
Gln-Gln-Tyr-Phe-NH2
-
pH 8.0, 30°C
46
Gln-Glu-Ala-Ala-NH2
-
pH 8.0, 30°C
39
Gln-Glu-Ala-Phe-NH2
-
pH 8.0, 30°C
45.6 - 45.8
Gln-Glu-Asp-Leu-NH2
42.1
Gln-Glu-Tyr-Ala-NH2
-
pH 8.0, 30°C
45.1
Gln-Glu-Tyr-NH2
-
pH 8.0, 30°C
46
Gln-Glu-Tyr-Phe-NH2
-
pH 8.0, 30°C
83
Gln-His-Pro-NH2
-
30°C, recombinant enzyme, expressed in Pichia pastoris
55.4
Gln-His-Tyr-Phe-NH2
-
pH 8.0, 30°C
31.6 - 33.4
Gln-Lys-Arg-Leu-NH2
7.5
Gln-Phe-Ala
-
protein version: shortened N-terminus, I73N/C369A, His-tagged, pH 8.0, 30°C, similar value with other protein versions
109
Gln-Phe-Ala-NH2
-
pH 8.0, 30°C
31.7
Gln-Pro-Tyr-Phe-NH2
-
pH 8.0, 30°C
52.8
Gln-Ser-Tyr-Phe-NH2
-
pH 8.0, 30°C
6.7 - 20.9
Gln-tert-butyl ester
94
Gln-Tyr
-
pH 8.0, 30°C
17.2
Gln-Val
-
pH 8.0, 30°C
10
glucagon(3-29)
-
pH 6.0, 30°C, 1% DMSO
-
1.07
H-Gln-7-amido-4-methylcoumarin
-
pH 8.0, 30°C
3.4
H-Gln-beta-naphthylamide
-
pH 8.0, 30°C
2.72
H-Gln-Gln-OH
-
pH 8.0, 30°C
2.65
H-Gln-Glu-OH
-
pH 8.0, 30°C
1.66
H-Gln-Gly-OH
-
pH 8.0, 30°C
4.02
H-Gln-Gly-Pro-OH
-
pH 8.0, 30°C
18.8
L-glutaminyl-2-naphthylamide
-
30°C, recombinant enzyme, expressed in Pichia pastoris
5.4
L-glutaminyl-4-methylcoumarinylamide
-
30°C, recombinant enzyme, expressed in Pichia pastoris
1.07
L-glutaminyl-7-amido-4-methylcoumarin
-
protein version: shortened N-terminus, I73N/C369A, His-tagged, pH 8.0, 30°C, similar value with other protein versions
3.4
L-glutaminyl-beta-naphthylamide
-
protein version: shortened N-terminus, I73N/C369A, His-tagged, pH 8.0, 30°C, similar value with other protein versions
20
N1-naphthalen-2-yl-L-glutamamide
-
pH 8.0, 30°C, 0.5 M KCl
6.4
QEDL
-
protein version: shortened N-terminus, I73N/C369A, His-tagged, pH 8.0, 30°C, similar value with other protein versions
3.3
QEYF
-
protein version: shortened N-terminus, I73N/C369A, His-tagged, pH 8.0, 30°C, similar value with other protein versions
69.6
[Gln1]-fertilization promoting peptide
-
pH 8.0, 30°C
-
54.1
[Gln1]-gastrin
-
pH 8.0, 30°C
-
69.2
[Gln1]-gonadotropin releasing-hormone
-
pH 8.0, 30°C
-
48.8
[Gln1]-neurotensin
-
pH 8.0, 30°C
82.8
[Gln1]-thyrotropin releasing-hormone
-
pH 8.0, 30°C
-
41.4
Gln(3)-amyloid-beta peptide 3-11 amide
-
pH 6.0, 30°C, 1% DMSO
-
55
Gln(3)-amyloid-beta peptide 3-11 amide
-
pH 6.0, 30°C, in absence of DMSO
-
0.0019
Gln-2-naphthylamide
-
pH 8.0, 25°C, mutant enzyme D305E
0.0042
Gln-2-naphthylamide
-
pH 8.0, 25°C, mutant enzyme D248Q
0.03
Gln-2-naphthylamide
-
pH 8.0, 25°C, mutant enzyme D305N
0.068
Gln-2-naphthylamide
-
pH 8.0, 25°C, mutant enzyme D305A
0.085
Gln-2-naphthylamide
-
pH 8.0, 25°C, mutant enzyme D248A
0.84
Gln-2-naphthylamide
-
pH 8.0, 25°C, mutant enzyme S160G
1
Gln-2-naphthylamide
-
pH 8.0, 25°C, mutant enzyme E201D
1
Gln-2-naphthylamide
-
pH 8.0, 25°C, mutant enzyme H319L
5.3
Gln-2-naphthylamide
-
pH 8.0, 25°C, mutant enzyme S160A
5.4
Gln-2-naphthylamide
-
pH 8.0, 25°C, wild-type enzyme
1.27
Gln-Ala
-
-
47.6
Gln-Ala
-
pH 8.0, 30°C, 0.5 M KCl
57.2
Gln-Ala
-
pH 8.0, 30°C
29.8
Gln-Arg-Gly-Ile-NH2
-
pH 8.0, 30°C, 0.5 M KCl
33.5
Gln-Arg-Gly-Ile-NH2
-
pH 8.0, 30°C
0.43
Gln-Gln
pH 8.0, mutant enzyme W207L
0.87
Gln-Gln
pH 8.0, mutant enzyme E201D
1.35
Gln-Gln
pH 8.0, mutant enzyme W329A
2.32
Gln-Gln
pH 8.0, mutant enzyme W207F
2.7
Gln-Gln
-
protein version: shortened N-terminus, I73N/C369A, His-tagged, pH 8.0, 30°C, similar value with other protein versions
7.3
Gln-Gln
pH 7.0, wild-type enzyme
7.35
Gln-Gln
pH 8.0, mutant enzyme R54W
7.91
Gln-Gln
pH 8.0, mutant enzyme F146A
8.56
Gln-Gln
pH 8.8, wild-type enzyme
8.63
Gln-Gln
pH 8.0, wild-type enzyme
9.39
Gln-Gln
pH 8.0, mutant enzyme Q304L
9.76
Gln-Gln
pH 7.5, wild-type enzyme
9.93
Gln-Gln
pH 8.5, wild-type enzyme
11.67
Gln-Gln
pH 8.0, mutant enzyme K144A
12.91
Gln-Gln
pH 8.0, mutant enzyme F325A
20.7
Gln-Gln
-
pH 8.0, 30°C
2.6
Gln-Glu
-
protein version: shortened N-terminus, I73N/C369A, His-tagged, pH 8.0, 30°C, similar value with other protein versions
18.9
Gln-Glu
-
pH 8.0, 30°C, 0.5 M KCl
24.7
Gln-Glu
-
pH 8.0, 30°C
45.6
Gln-Glu-Asp-Leu-NH2
-
pH 8.0, 30°C, 0.5 M KCl
45.8
Gln-Glu-Asp-Leu-NH2
-
pH 8.0, 30°C
0.368
Gln-Gly
-
-
1.65
Gln-Gly
-
protein version: shortened N-terminus, I73N/C369A, His-tagged, pH 8.0, 30°C, similar value with other protein versions
13.2
Gln-Gly
-
pH 8.0, 30°C
4
Gln-Gly-Pro
-
protein version: shortened N-terminus, I73N/C369A, His-tagged, pH 8.0, 30°C, similar value with other protein versions
25.3
Gln-Gly-Pro
-
pH 8.0, 30°C
31.6
Gln-Lys-Arg-Leu-NH2
-
pH 8.0, 30°C, 0.5 M KCl
33.4
Gln-Lys-Arg-Leu-NH2
-
pH 8.0, 30°C
0.36
Gln-NH2
-
mutant enzyme H319Q
0.388
Gln-NH2
-
mutant enzyme H307Q
0.435
Gln-NH2
-
unmutated enzyme
12.2
Gln-NH2
-
pH 8.0, 30°C, 0.5 M KCl
12.8
Gln-NH2
-
pH 8.0, 30°C
20.7
Gln-NH2
-
30°C, recombinant enzyme, expressed in Pichia pastoris
6.7
Gln-tert-butyl ester
-
pH 8.0, 30°C
16
Gln-tert-butyl ester
-
-
20.9
Gln-tert-butyl ester
-
-
47
Gln-Trp-Ala-NH2
-
pH 8.0, 30°C
50
Gln-Trp-Ala-NH2
-
pH 8.0, 30°C, 0.5 M KCl
7.7
Gln-Tyr-Ala
-
protein version: shortened N-terminus, I73N/C369A, His-tagged, pH 8.0, 30°C, similar value with other protein versions
125
Gln-Tyr-Ala
-
pH 8.0, 30°C
125
Gln-Tyr-Ala-OH
-
30°C, recombinant enzyme, expressed in Pichia pastoris
220
Gln-Tyr-Ala-OH
-
37°C, recombinant enzyme, expressed in Pichia pastoris
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.253
(3,4-dichlorophenyl)-2-cyano-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)guanidine
-
0.62
(3-(1H-imidazol-1-yl)propyl)-2-cyano-3-(2,3-dihydrobenzo[b][1,4]dioxin-7-yl)guanidine
-
1.36
(3-(1H-imidazol-1-yl)propyl)-2-cyano-3-(3,4-dimethoxyphenyl)guanidine
-
6.72
(3-(1H-imidazol-1-yl)propyl)-2-cyano-3-(4-(trifluoromethyl)phenyl)guanidine
-
0.83
(3-(1H-imidazol-1-yl)propyl)-2-cyano-3-(4-isopropylphenyl)guanidine
-
0.7
(3-(1H-imidazol-1-yl)propyl)-2-cyano-3-(4-methoxyphenyl)guanidine
-
1.37
(3-(1H-imidazol-1-yl)propyl)-2-cyano-3-(cyclopropylmethyl)guanidine
-
1.53
(3-(1H-imidazol-1-yl)propyl)-2-cyano-3-methylguanidine
-
1.02
(3-(1H-imidazol-1-yl)propyl)-2-cyano-3-phenylguanidine
-
1.09
(3-(1H-imidazol-1-yl)propyl)-3-(4-bromophenyl)-2-cyanoguanidine
-
1.65
(3-(4-methyl-1H-imidazol-1-yl)propyl)-2-cyano-3-(2,3-dihydrobenzo[b][1,4]dioxin-7-yl)guanidine
-
0.13
(3-(5-methyl-1H-imidazol-1-yl)propyl)-2-cyano-3-(2,3-dihydrobenzo[b][1,4]dioxin-7-yl)guanidine
-
0.295
1,4-bis-(imidazol-1-yl)methyl-2,5-dimethylbenzene
30°C, pH 8.0
0.00112
1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[3-(1H-imidazol-1-yl)propyl]thiourea
-
pH 8.0, 30°C
0.00056
1-(2,4-dimethoxyphenyl)-3-[3-(1H-imidazol-1-yl)propyl]thiourea
-
pH 8.0, 30°C
0.184
1-(2-oxo-2-phenylethyl)-imidazole
30°C, pH 8.0
0.00155
1-(3,4-dimethoxybenzyl)-3-[3-(1H-imidazol-1-yl)propyl]thiourea
-
pH 8.0, 30°C
0.00233
1-(3,4-dimethoxyphenyl)-3-(2-[1-(1H-imidazol-1-yl)cyclopropyl]ethyl)thiourea
-
pH 8.0, 30°C
0.06
1-(3,4-dimethoxyphenyl)-3-(3-(4-methyl-1H-imidazol-1-yl)propyl)thiourea
-
0.0063
1-(3,4-dimethoxyphenyl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
0.00034
1-(3,4-dimethoxyphenyl)-3-[(3R)-3-(1H-imidazol-1-yl)butyl]thiourea
-
pH 8.0, 30°C
0.00076
1-(3,4-dimethoxyphenyl)-3-[(3S)-3-(1H-imidazol-1-yl)butyl]thiourea
-
pH 8.0, 30°C
0.00006
1-(3,4-dimethoxyphenyl)-3-[3-(1H-imidazol-1-yl)propyl]thiourea
-
pH 8.0, 30°C
0.00049
1-(3,4-dimethoxyphenyl)-3-[3-(1H-imidazol-1-yl)propyl]urea
-
pH 8.0, 30°C
0.00055
1-(3,4-dimethoxyphenyl)-3-[4-(1H-imidazol-1-yl)butyl]thiourea
-
pH 8.0, 30°C
0.041
1-(3,4-dimethoxyphenyl)-N-(3-(4-methyl-1H-imidazol-1-yl)propyl)cyclopropanecarbothioamide
-
0.0026
1-(3,4-dimethoxyphenyl)-N-(3-(5-methyl-1H-imidazol-1-yl)propyl)cyclopropanecarbothioamide
-
0.00075
1-(3,5-dimethoxyphenyl)-3-[3-(1H-imidazol-1-yl)propyl]thiourea
-
pH 8.0, 30°C
0.41
1-(3-aminopropyl)-imidazole
30°C, pH 8.0
0.0018
1-(4-acetylphenyl)-3-[3-(1H-imidazol-1-yl)propyl]thiourea
-
pH 8.0, 30°C
0.00089
1-(4-ethoxyphenyl)-3-[3-(1H-imidazol-1-yl)propyl]thiourea
-
pH 8.0, 30°C
0.0028
1-(4-ethylphenyl)-3-[3-(1H-imidazol-1-yl)propyl]thiourea
-
pH 8.0, 30°C
0.0062
1-(6-phenoxyhexyl)-1H-imidazole
-
0.000262 - 0.0071
1-Benzylimidazole
0.12
1-methyl-5-(beta-aminoethyl)-imidazole
30°C, pH 8.0
0.03
1-Methylimidazole
30°C, pH 8.0
0.049
1-vinylimidazole
30°C, pH 8.0
0.0028
1-[3-(1H-imidazol-1-yl)propyl]-3-(1-naphthyl)thiourea
-
pH 8.0, 30°C
0.00034
1-[3-(1H-imidazol-1-yl)propyl]-3-(3,4,5-trimethoxyphenyl)thiourea
-
pH 8.0, 30°C
0.00186
1-[3-(1H-imidazol-1-yl)propyl]-3-(3-methoxyphenyl)thiourea
-
pH 8.0, 30°C
0.0007
1-[3-(1H-imidazol-1-yl)propyl]-3-(4-methoxyphenyl)thiourea
-
pH 8.0, 30°C
0.00214
1-[3-(1H-imidazol-1-yl)propyl]-3-(4-methylphenyl)thiourea
-
pH 8.0, 30°C
0.00166
1-[3-(1H-imidazol-1-yl)propyl]-3-[4-(methylthio)phenyl]thiourea
-
pH 8.0, 30°C
0.00097
1-[4-(benzyloxy)phenyl]-3-[3-(1H-imidazol-1-yl)propyl]thiourea
-
pH 8.0, 30°C
0.23
2,3-dihydro-3-(3-(4-methyl-1H-imidazol-1-yl)propyl)-2-thioxoquinazolin-4(1H)-one
-
0.018
2,3-dihydro-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)-2-thioxoquinazolin-4(1H)-one
-
0.083
2,3-dihydro-6-methyl-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)-5-phenyl-2-thioxothieno[2,3-d]pyrimidin-4(1H)-one
-
1.8
2-aminobenzimidazole
30°C, pH 8.0
0.061
2-cyano(3,4,5-trimethoxyphenyl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)guanidine
-
0.082
2-cyano(3-(5-methyl-1H-imidazol-1-yl)propyl)-3-(3,4-dimethylphenyl)guanidine
-
0.065
2-cyano-1-[3-(5-methyl-1H-imidazol-1-yl)propyl]-4-phenylbenzene-1-guanidine
-
0.58
2-ethyl-4-methyl-imidazole
30°C, pH 8.0
0.165
2-methyl-benzylimidazole
30°C, pH 8.0
0.3
3-(3-(1H-imidazol-1-yl)propyl)-2,3-dihydro-2-thioxoquinazolin-4(1H)-one
-
0.36
3-(3-(1H-imidazol-1-yl)propyl)-2,3-dihydro-7-methyl-2-thioxothieno[3,2-d]pyrimidin-4(1H)-one
-
0.62
3-[3-(1H-imidazol-1-yl)propyl]-2-thioxo-1,2,3,5,6,7-hexahydro-4H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-one
-
0.9
3-[3-(1H-imidazol-1-yl)propyl]-2-thioxo-2,3,5,6,7,8,9,10-octahydrocycloocta[4,5]thieno[2,3-d]pyrimidin-4(1H)-one
-
0.34
3-[3-(1H-imidazol-1-yl)propyl]-2-thioxo-2,3,5,6,7,8-hexahydro[1]benzothieno[2,3-d]pyrimidin-4(1H)-one
-
0.818
3-[3-(1H-imidazol-1-yl)propyl]-2-thioxoimidazolidin-4-one
30°C, pH 8.0
0.039
3-[3-(5-methyl-1H-imidazol-1-yl)propyl]-2-thioxo-2,3,5,6,7,8,9,10-octahydrocycloocta[4,5]-thieno[2,3-d]pyrimidin-4(1H)-one
-
0.017
3-[3-(5-methyl-1H-imidazol-1-yl)propyl]-2-thioxo-2,3,5,6,7,8-hexahydro[1]benzothieno[2,3-d]pyrimidin-4(1H)-one
-
0.0023
4-(2-imidazol-1-yl-ethoxy)-benzoic acid
30°C, pH 8.0
7.6
4-imidazole-carboxaldehyde
30°C, pH 8.0
0.000023
5-(5-[[(3,4-dimethoxyphenyl)sulfanyl]methyl]-1,3,4-oxadiazol-2-yl)-1H-benzimidazole
pH and temperature not specified in the publication
0.00101
5-(5-[[(pyridin-4-yl)methyl]sulfanyl]-1,3,4-oxadiazol-2-yl)-1H-benzimidazole
pH and temperature not specified in the publication
15.5
5-amino-3H-imidazole-4-carboxylic acid amide
30°C, pH 8.0
0.129
5-hydroxymethyl-4-methyl-imidazole
30°C, pH 8.0
0.000638
5-[5-(2-phenylethyl)-1,3,4-oxadiazol-2-yl]-1H-benzimidazole
pH and temperature not specified in the publication
0.02
6-benzyl-2,3-dihydro-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)-2-thioxothieno[2,3-d]pyrimidin-4(1H)-one
-
0.138 - 0.25
benzimidazole
0.0062 - 0.0073
benzylimidazole
0.068
cysteamine
-
pH 8.0, 30°C
4.69 - 8.32
EFRHHDSGYE-NH2
0.97 - 1.21
Gln-tert-butyl ester
5.73
H-Gln-7-amido-4-methylcoumarin
-
-
1.47
H-Gln-beta-naphthylamide
-
-
0.6
H-His-Trp-OH
30°C, pH 8.0
14.5
imidazol-4-carbonic acid methylester
30°C, pH 8.0
4.47
L-glutaminyl-7-amido-4-methylcoumarin
-
protein version: shortened N-terminus, I73N/C369A, His-tagged, pH 8.0, 30°C, similar value with other protein versions
1.57
L-glutaminyl-beta-naphthylamide
-
protein version: shortened N-terminus, I73N/C369A, His-tagged, pH 8.0, 30°C, similar value with other protein versions
0.85
L-histamine
30°C, pH 8.0
0.56
L-histidinamide
30°C, pH 8.0
4.4
L-histidine
30°C, pH 8.0
1.53
L-histidinol
30°C, pH 8.0
0.079 - 0.082
methylimidazole
0.051
N-(-1-(3-(5-methyl-1H-imidazol-1-yl)propylamino)-2-nitrovinyl)-4-chloro-benzenamine
-
0.54
N-(1-(3-(1H-imidazol-1-yl)propylamino)-2-nitrovinyl)-2,3-dihydrobenzo[b][1,4]-dioxin-6-amine
-
0.61
N-(1-(3-(1H-imidazol-1-yl)propylamino)-2-nitrovinyl)-3,4-dimethoxy-benzenamine
-
0.54
N-(1-(3-(1H-imidazol-1-yl)propylamino)-2-nitrovinyl)-4-(trifluoromethyl)-benzenamine
-
0.57
N-(1-(3-(1H-imidazol-1-yl)propylamino)-2-nitrovinyl)-4-chlorobenzenamine
-
1.03
N-(1-(3-(1H-imidazol-1-yl)propylamino)-2-nitrovinyl)-4-methoxybenzenamine
-
1.17
N-(1-(3-(1H-imidazol-1-yl)propylamino)-2-nitrovinyl)benzenamine
-
0.52
N-(1-(3-(1H-imidazol-1-yl)propylamino)-2-nitrovinyl)naphthalen-1-amine
-
1.29
N-(1-(3-(4-methyl-1H-imidazol-1-yl)propylamino)-2-nitrovinyl)-2,3-dihydrobenzo[b][1,4]-dioxin-6-amine
-
0.067
N-(1-(3-(5-methyl-1H-imidazol-1-yl)propylamino)-2-nitrovinyl)-2,3-dihydrobenzo[b][1,4]-dioxin-6-amine
-
0.034
N-(1-(3-(5-methyl-1H-imidazol-1-yl)propylamino)-2-nitrovinyl)-4-(trifluoromethyl)benzenamine
-
0.044
N-(1-(3-(5-methyl-1H-imidazol-1-yl)propylamino)-2-nitrovinyl)cyclohexanamine
-
0.042
N-(1-(3-(5-methyl-1H-imidazol-1-yl)propylamino)-2-nitrovinyl)naphthalen-1-amine
-
0.000006
N-(3,4-dimethoxyphenyl)-N'-[3-(1H-imidazol-1-yl)propyl]thiourea
pH and temperature not specified in the publication
0.5
N-(3-(1H-imidazol-1-yl)propyl)-N-cyclohexyl-2-nitroethene-1,1-diamine
-
20.55
N-(3-(1H-imidazol-1-yl)propyl)-N-methyl-2-nitroethene-1,1-diamine
-
0.0012
N-(4-chlorophenyl)-N'-[2-(1H-imidazol-1-yl)propyl]-2-thioxoimidazolidin-4-one
30°C, pH 8.0
0.00124
N-(4-chlorophenyl)-N'-[3-(1H-imidazol-1-yl)propyl]thiourea
pH and temperature not specified in the publication
0.167
N-(trimethylsilyl)-imidazole
30°C, pH 8.0
0.107
N-Acetylimidazole
30°C, pH 8.0
0.174
N-benzoylimidazole
30°C, pH 8.0
0.022
N-dimethylcysteamine
-
pH 8.0, 30°C
0.017
N-omega-acetylhistamine
30°C, pH 8.0
0.002
N-[3-(1H-imidazol-1-yl)propyl]-5-methoxy-1,3-benzothiazol-2-amine
-
pH 8.0, 30°C
0.00157
N-[3-(1H-imidazol-1-yl)propyl]-6-methoxy-1,3-benzothiazol-2-amine
-
pH 8.0, 30°C
0.001698 - 0.005748
Nomega-acetylhistamine
0.078
oxalic acid diimidazolidide
30°C, pH 8.0
0.000095 - 0.001817
PBD150
0.00002
SEN177
pH 8.0, 25°C, with enzyme mutant Y115E/Y117E
additional information
additional information
-
0.000262
1-Benzylimidazole
Golgi-resident glutaminyl cyclase, at 25°C in 50 mM Tris-HCl, pH 8.0
0.000607
1-Benzylimidazole
secretory glutaminyl cyclase, at 25°C in 50 mM Tris-HCl, pH 8.0
0.0071
1-Benzylimidazole
30°C, pH 8.0
0.138
benzimidazole
30°C, pH 8.0
0.199
benzimidazole
-
pH 8.0, 30°C
0.25
benzimidazole
-
protein version: shortened N-terminus, I73N/C369A, His-tagged, pH 8.0, 30°C, similar value with other protein versions
0.0062
benzylimidazole
-
protein version: shortened N-terminus, I73N/C369A, His-tagged, pH 8.0, 30°C, similar value with other protein versions
0.0073
benzylimidazole
-
pH 8.0, 30°C
1.824
cacodylate
secretory glutaminyl cyclase, at 25°C in 50 mM Tris-HCl, pH 8.0
6.696
cacodylate
Golgi-resident glutaminyl cyclase, at 25°C in 50 mM Tris-HCl, pH 8.0
3.25
EFRH-NH2
-
at pH 8.0
24.64
EFRH-NH2
-
at pH 6.0
4.69
EFRHHDSGYE-NH2
-
at pH 8.0
8.32
EFRHHDSGYE-NH2
-
at pH 6.0
0.97
Gln-tert-butyl ester
-
pH 8.0, 30°C, 0.5 M KCl
1.21
Gln-tert-butyl ester
-
pH 8.0, 30°C
0.103
imidazole
30°C, pH 8.0
0.219
imidazole
-
pH 8.0, 30°C
0.235
imidazole
-
protein version: shortened N-terminus, I73N/C369A, His-tagged, pH 8.0, 30°C, similar value with other protein versions
0.079
methylimidazole
-
pH 8.0, 30°C
0.082
methylimidazole
-
protein version: shortened N-terminus, I73N/C369A, His-tagged, pH 8.0, 30°C, similar value with other protein versions
0.001698
Nomega-acetylhistamine
secretory glutaminyl cyclase, at 25°C in 50 mM Tris-HCl, pH 8.0
0.005748
Nomega-acetylhistamine
Golgi-resident glutaminyl cyclase, at 25°C in 50 mM Tris-HCl, pH 8.0
0.000095
PBD150
secretory glutaminyl cyclase, at 25°C in 50 mM Tris-HCl, pH 8.0
0.0001
PBD150
wild type enzyme, in 50 mM Tris, pH 8.0, at 30°C
0.001817
PBD150
Golgi-resident glutaminyl cyclase, at 25°C in 50 mM Tris-HCl, pH 8.0
additional information
additional information
inhibition kinetics
-
additional information
additional information
inhibition kinetics
-
additional information
additional information
-
inhibition kinetics
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.0003
5,6-dimethoxy-N-[3-(5-methyl-1H-imidazol-1-yl)propyl]-1,3-benzothiazol-2-amine
Homo sapiens
pH 7.0, 37°C
0.00011
5,6-dimethoxy-N-[3-(5-methyl-1H-imidazol-1-yl)propyl]-1H-benzimidazol-2-amine
Homo sapiens
pH 7.0, 37°C
0.00007
5-(5-[[(3,4-dimethoxyphenyl)sulfanyl]methyl]-1,3,4-oxadiazol-2-yl)-1H-benzimidazole
Homo sapiens
pH and temperature not specified in the publication
0.00396
5-[5-(2-phenylethyl)-1,3,4-oxadiazol-2-yl]-1H-benzimidazole
Homo sapiens
pH and temperature not specified in the publication
0.00064
methyl N-[(2S)-1-hydroxy-2-[[3-(5-methyl-1H-imidazol-1-yl)propyl]amino]-3-phenylpropyl]-L-alaninate
Homo sapiens
pH 7.0, 37°C
0.0000064
N-((E)-4-(3-(4-(2-aminoethyl)piperazin-1-yl)-3-oxoprop-1-en-1-yl)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
Homo sapiens
pH and temperature not specified in the publication
0.0000194
N-((E)-4-(3-oxo-3-(piperazin-1-yl)prop-1-en-1-yl)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
Homo sapiens
pH and temperature not specified in the publication
0.000026
N-((E)-4-(3-oxo-3-(piperidin-4-ylamino)prop-1-en-1-yl)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
Homo sapiens
pH and temperature not specified in the publication
0.00032
N-(3,4-dimethoxyphenyl)-4-[2-(5-methyl-1H-imidazol-1-yl)ethyl]-1,3-thiazol-2-amine
Homo sapiens
pH 7.0, 37°C
0.00042
N-(3,4-dimethoxyphenyl)-5-[2-(5-methyl-1H-imidazol-1-yl)ethyl]-1,3,4-oxadiazol-2-amine
Homo sapiens
pH 7.0, 37°C
0.000029 - 0.0000292
N-(3,4-dimethoxyphenyl)-N'-[3-(5-methyl-1H-imidazol-1-yl)propyl]thiourea
0.0000264
N-(3-(2-(2-aminopyridin-4-yl)ethoxy)-4-methoxyphenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
Homo sapiens
pH and temperature not specified in the publication
0.0000079
N-(3-(2-aminoethoxy)-4-methoxyphenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
Homo sapiens
pH and temperature not specified in the publication
0.000015
N-(3-(3-(2-aminopyridin-4-yl)propoxy)-4-methoxyphenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
Homo sapiens
pH and temperature not specified in the publication
0.000009
N-(3-(3-aminopropoxy)-4-methoxyphenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
Homo sapiens
pH and temperature not specified in the publication
0.0000159
N-(3-(4-(2-aminopyridin-4-yl)butoxy)-4-methoxyphenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
Homo sapiens
pH and temperature not specified in the publication
0.0000468
N-(3-(4-(dimethylamino)butoxy)-4-methoxyphenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
Homo sapiens
pH and temperature not specified in the publication
0.0000088
N-(3-(4-aminobutoxy)-4-methoxyphenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
Homo sapiens
pH and temperature not specified in the publication
0.0000062
N-(3-methoxy-4-[[4-(piperidin-4-yl)phenyl]methoxy]phenyl)-N'-[3-(5-methyl-1H-imidazol-1-yl)propyl]thiourea
Homo sapiens
pH and temperature not specified in the publication
0.0000162
N-(4-((1-(2-aminoethyl)piperidin-4-yl)carbamoyl)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
Homo sapiens
pH and temperature not specified in the publication
0.0000565
N-(4-(2-(((2-aminopyridin-4-yl)methyl)amino)-2-oxoethoxy)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
Homo sapiens
pH and temperature not specified in the publication
0.0000079
N-(4-(2-((1-(2-aminoethyl)piperidin-4-yl)amino)-2-oxoethoxy)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
Homo sapiens
pH and temperature not specified in the publication
0.0000187
N-(4-(2-(piperazin-1-yl)ethoxy)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
Homo sapiens
pH and temperature not specified in the publication
0.0000114
N-(4-(2-oxo-2-(piperazin-1-yl)ethoxy)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
Homo sapiens
pH and temperature not specified in the publication
0.0000129
N-(4-(2-oxo-2-(piperidin-4-ylamino)ethoxy)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
Homo sapiens
pH and temperature not specified in the publication
0.0000247
N-(4-(4-(2-aminopyridin-4-yl)butoxy)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
Homo sapiens
pH and temperature not specified in the publication
0.0000206
N-(4-methoxy-3-(2-(1-methylpiperidin-4-yl)ethoxy)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
Homo sapiens
pH and temperature not specified in the publication
0.0000184
N-(4-methoxy-3-(2-(piperazin-1-yl)ethoxy)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
Homo sapiens
pH and temperature not specified in the publication
0.0000073
N-(4-methoxy-3-(2-(piperidin-4-yl)ethoxy)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
Homo sapiens
pH and temperature not specified in the publication
0.0000268
N-(4-methoxy-3-(3-(methylamino)propoxy)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
Homo sapiens
pH and temperature not specified in the publication
0.0000158
N-(4-methoxy-3-(3-(piperazin-1-yl)propoxy)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
Homo sapiens
pH and temperature not specified in the publication
0.0000088
N-(4-methoxy-3-(3-(piperidin-4-yl)propoxy)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
Homo sapiens
pH and temperature not specified in the publication
0.000022
N-(4-methoxy-3-(4-(methylamino)butoxy)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
Homo sapiens
pH and temperature not specified in the publication
0.000015
N-(4-methoxy-3-(4-(piperazin-1-yl)butoxy)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
Homo sapiens
pH and temperature not specified in the publication
0.0000079
N-(4-methoxy-3-(4-(piperidin-4-yl)butoxy)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
Homo sapiens
pH and temperature not specified in the publication
0.0000152
N-(4-methoxy-3-(4-(pyrimidin-2-ylamino)butoxy)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
Homo sapiens
pH and temperature not specified in the publication
0.0000112
N-(E)-(4-(3-(4-(2-aminoethyl)piperazin-1-yl)-3-oxoprop-1-en-1-yl)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
Homo sapiens
pH and temperature not specified in the publication
0.0000088
N-[3-(4-aminobutoxy)-4-methoxyphenyl]-N'-[3-(2-methyl-1H-imidazol-1-yl)propyl]thiourea
Homo sapiens
pH and temperature not specified in the publication
0.00045
N2-[(2S)-1-hydroxy-2-[[3-(5-methyl-1H-imidazol-1-yl)propyl]amino]-3-phenylpropyl]-L-alaninamide
Homo sapiens
pH 7.0, 37°C
0.0053
PBD150
Homo sapiens
pH and temperature not specified in the publication
0.0000247
PQ912
Homo sapiens
pH 8.0, 25°C
0.000053
SEN-177
Homo sapiens
pH and temperature not specified in the publication
0.00017
SEN-180
Homo sapiens
pH and temperature not specified in the publication
0.0018
SEN-817
Homo sapiens
pH and temperature not specified in the publication
0.000013 - 0.00005
SEN177
0.000058
Sen180
Homo sapiens
pH and temperature not specified in the publication
0.0023
Sen817
Homo sapiens
pH and temperature not specified in the publication
0.000029
N-(3,4-dimethoxyphenyl)-N'-[3-(5-methyl-1H-imidazol-1-yl)propyl]thiourea
Homo sapiens
pH 7.0, 37°C
0.0000292
N-(3,4-dimethoxyphenyl)-N'-[3-(5-methyl-1H-imidazol-1-yl)propyl]thiourea
Homo sapiens
pH and temperature not specified in the publication
0.000013
SEN177
Homo sapiens
pH and temperature not specified in the publication
0.00005
SEN177
Homo sapiens
pH 8.0, 25°C, with enzyme mutant Y115E/Y117E
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
evolution
glutaminyl cyclase (QC) and isoglutaminyl cyclase (isoQC) belong to the family of the metalloenzymes
evolution
glutaminyl cyclase (QC, glutaminyl-peptide cyclotransferase (QPCT)) and its isoenzyme isoQC (QPCTL) belong to a family of enzymes which catalyze the formation of pyroglutamate (pGlu, pE) at N-terminus of proteins by converting glutamate/glutamine to pGlu residue
evolution
glutaminyl cyclases (QCs) belong to the class of acyl transferases. Different types of QCs are identified in bacteria, plants and animals, including mammalian tissues
malfunction
glutaminyl cyclase inhibitors alter the CD47 protein by inhibiting QPCTL function and the resulting block in pGlu-modified CD47 is nearly complete. The expansion, differentiation, cytokine production and killing capacity of human T cells is compatible with small molecule inhibition of QPCTL. But QPCTL deficiency and QPCTL inhibition enhance tumor cell control by tumor-specific antibodies
malfunction
knockout of isoQC dramatically reduces the binding of SIRPalpha to cell surface
malfunction
loss of the pE-modification and N-terminal charge leads to accelerated aggregation of Abeta3(pE) compared with unmodified Abeta
metabolism
the activity of myeloid cells such as macrophages and neutrophils is likewise regulated by a balance between stimulatory and inhibitory signals. In particular, cell surface expression of the CD47 protein creates a 'don't eat me' signal on tumor cells by binding to SIRPalpha expressed on myeloid cells. CD47 is a broadly expressed inhibitory ligand for myeloid cells. The glutaminyl-peptide cyclotransferase-like protein (QPCTL) is a major component of the CD47-SIRPalpha checkpoint. Interference with QPCTL expression leads to a major increase in neutrophil-mediated killing of tumor cells in vivo. Diglutamate formation occurs early in the CD47 protein life cycle and fully depends on QPCTL. Synergy between blockade of CD47 diglutamate formation and tumor opsonization in tumor cell killing by macrophages and neutrophils
metabolism
the dipeptidyl-peptidase activity of meprin beta links N-truncation of Abeta with glutaminyl cyclase-catalyzed pGlu-Abeta formation
metabolism
transmembrane protein CD47 is highly expressed on many types of cancer cells and can directly bind to the receptor signal regulatory protein alpha (SIRPalpha), which is highly expressed on phagocytic cells. Binding of CD47 to SIRPalpha can protect cancer cells from phagocytosis by phagocytic cells and therefore functions as the major 'don't eat me' signal. Therapeutic blockade of CD47-SIRPalpha axis can efficiently promote the macrophage-mediated phagocytosis and elimination of cancer cells. Glutaminyl cyclase isoenzyme isoQC is a regulator of SIRPalpha-CD47 axis
physiological function
-
glutaminyl cyclase contributes to the formation of focal and diffuse diglutamate-Abeta peptide deposits in hippocampus
physiological function
amyloid-beta peptide Abeta3-40/42 is the precursor of pGlu-Abeta3-40/42 generated by glutaminyl cyclase (QC). The formation of amyloid-beta (Abeta) peptides is causally involved in the development of Alzheimer's disease (AD)
physiological function
glutaminyl cyclase (QC) and isoglutaminyl cyclase (isoQC) catalyze the intramolecular cyclization of N-terminal L-glutamine/glutamate residues of certain proteins into diglutamic acid (pGlu). The amyloid protein and the monocyte chemoattractant protein (MCP-1) also known as CCL2 that promotes a cascade of inflammation-related responses are two representative substrates. The diglutamated Abeta and CCL2 exhibit more severe neurotoxicity than normal Abeta and CCL2. The Abeta1-40/42 peptides start with an L-aspartate at the N-terminus. Under pathological conditions, the Abeta1-40/42 peptides are truncated to expose the glutamate at position 3 or 11 of the Abeta peptides. Then the N-terminal glutamate (E) will be cyclized by QC to form the pyroglutamate (pE) and the products are termed as Abeta3(pE)-40/42 or Abeta11(pE)-40/42. The pE-modification of Abeta confers unique properties, such as proteolytic resistance. pGlu-Abeta peptides exhibit enhanced toxicity compared to the unmodified Abeta peptide and promote the formation of tau tangles. In Alzheimer's disease (AD) patients and animal AD models, the level and activity of QC are significantly increased
physiological function
glutaminyl cyclase (QC) and isoglutaminyl cyclase (isoQC) catalyze the intramolecular cyclization of N-terminal L-glutamine/glutamate residues of certain proteins into diglutamic acid (pGlu). The level of CCL2 and h-isoQCmRNA in Alzheimer disease (AD) patients is significantly higher than that of healthy subjects
physiological function
glutaminyl cyclase (QC) is one kind of acyltransferases, which catalyzes intramolecular cyclization of N-terminal glutamine residues to diglutamic acid (pGlu) with the concomitant liberation of ammonia. The post-translational formation of pGlu is an important process for the maturation of various bioactive neuropeptides, hormones, cytokines and for their biological activity, because the pGlu is required to protect the N termini from exopeptidase degradation and/or to develop the proper conformation. QC is abundant in mammalian secretory tissue such as secretory glands or brain tissue including hippocampus and cortex. Glutaminyl cyclase (QC) plays an important role in the initiation of the formation of neurotoxic plaques and in the pathogenesis of Alzheimer's disease (AD) due to the ability of human QC (hQC) to convert the N-terminal glutamate of beta-amyloids (Abetas) into respective pGlu-modified Abetas (pE-Abetas)
physiological function
glutaminyl cyclase activity correlates with levels of Abeta38, Abeta40 and angiogenesis mediators Flt1, Tie2, VEGFD, CAM-1 and ICAM-1 in cerebrospinal fluid of Alzheimers disease patients, core CSF diagnostic biomarkers (Abeta42, tau and p-tau) are not part of the diagnostic workup, detailed overview. Pyroglutamylation of truncated Abeta peptides, which is catalysed by enzyme glutaminyl cyclase (QC), generates pE-Abeta species with enhanced aggregation propensities and resistance to most amino-peptidases and endo-peptidases. pE-Abeta species have been identified as major constituents of Abeta plaques and reduction of pE-Abeta species is associated with improvement of cognitive tasks in animal models of Alzheimer's disease (AD). Some inflammatory or angiogenesis mediators are potential QC substrates
physiological function
glutaminyl cyclase isoenzyme isoQC is an essential regulator of CD47-SIRPalpha axis and required for efficient phagocytic cells-mediated clearance of cancer cells. N-terminal pGlu modification of proteins may protect protein from degradation by proteases or promote protein aggregation
physiological function
glutaminyl cyclases (QCs) catalyze the intramolecular cyclization of N-terminal L-glutamine residues of peptides and proteins into pyroglutamic acid (5-oxo-prolyl, pGlu, pE) releasing ammonia, as well as the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid. Such a type of post-translational modification stabilizes the peptides and proteins, protects them from proteolytic degradation, and can be important for their biological activity
physiological function
human glutaminyl cyclase (hQC) is an important enzyme for post-translational modification by converting the N-terminal glutaminyl and glutamyl into diglutamate (pGlu) through cyclization. The two isoforms of hQC, secretory glutaminyl cyclase (sQC) and Golgi resident glutaminyl cyclase (gQC), are involved in various pathological conditions especially in Alzheimer's disease (AD). The sQC is known to mediate the formation of diglutamate containing amyloid beta (pGlu-Abeta) peptides while gQC mediates the maturation of C-C motif chemokine ligand 2 (CCL2)
physiological function
the glutaminyl-peptide cyclotransferase-like protein (QPCTL) is a Golgi-resident enzyme that, like its secreted family member QPCT, can catalyze the cyclization of N-terminal glutamine and glutamic acid residues on target proteins into an N-terminal pyroglutamate residue (pGlu). QPCTL is a major component of the CD47-SIRPalpha checkpoint. Diglutamate formation occurs early in the CD47 protein life cycle and fully depends on QPCTL. QPCTL is critical for diglutamate formation on CD47 at the SIRPalpha binding site shortly after biosynthesis. QPCTL is a modulator of CD47-SIRPalpha binding. Genetic and pharmacological interference with QPCTL activity enhances antibody-dependent cellular phagocytosis and cellular cytotoxicity of tumor cells. Interference with QPCTL expression leads to a major increase in neutrophil-mediated killing of tumor cells in vivo
additional information
active site structure of gQC, residue W231 in gQC has adopted an outward positioning of the indole ring and is involved in hydrogen bonding with one of the neighboring amino acid P256. Substrate binding and structural analysis, detailed overview. In both QC isozymes, three acidic residues (E201, D248, and D305 in sQC, and E225, D269 and D326 in gQC) are pointed to each other and are likely to form hydrogen bonds between them. These residues play a major role in the catalysis. Catalytic reaction mechanism
additional information
active site structure of gQC, residue W231 in gQC has adopted an outward positioning of the indole ring and is involved in hydrogen bonding with one of the neighboring amino acid P256. Substrate binding and structural analysis, detailed overview. In both QC isozymes, three acidic residues (E201, D248, and D305 in sQC, and E225, D269 and D326 in gQC) are pointed to each other and are likely to form hydrogen bonds between them. These residues play a major role in the catalysis. Catalytic reaction mechanism
additional information
-
active site structure of gQC, residue W231 in gQC has adopted an outward positioning of the indole ring and is involved in hydrogen bonding with one of the neighboring amino acid P256. Substrate binding and structural analysis, detailed overview. In both QC isozymes, three acidic residues (E201, D248, and D305 in sQC, and E225, D269 and D326 in gQC) are pointed to each other and are likely to form hydrogen bonds between them. These residues play a major role in the catalysis. Catalytic reaction mechanism
additional information
two active site conformations are reported for sQC (Conf-A and Conf-B) and these are mainly associated with the orientation of W207. In Conf-A (open), the orientation of the indole ring of W207 is towards the surface of the molecule and in Conf-B (closed), the orientation is towards the Zn2+ ion. Substrate binding and structural analysis, detailed overview. In both QC isozymes, three acidic residues (E201, D248, and D305 in sQC, and E225, D269 and D326 in gQC) are pointed to each other and are likely to form hydrogen bonds between them. These residues play a major role in the catalysis. Residues C139 and C164 are not involved in catalysis. Catalytic reaction mechanism
additional information
two active site conformations are reported for sQC (Conf-A and Conf-B) and these are mainly associated with the orientation of W207. In Conf-A (open), the orientation of the indole ring of W207 is towards the surface of the molecule and in Conf-B (closed), the orientation is towards the Zn2+ ion. Substrate binding and structural analysis, detailed overview. In both QC isozymes, three acidic residues (E201, D248, and D305 in sQC, and E225, D269 and D326 in gQC) are pointed to each other and are likely to form hydrogen bonds between them. These residues play a major role in the catalysis. Residues C139 and C164 are not involved in catalysis. Catalytic reaction mechanism
additional information
-
two active site conformations are reported for sQC (Conf-A and Conf-B) and these are mainly associated with the orientation of W207. In Conf-A (open), the orientation of the indole ring of W207 is towards the surface of the molecule and in Conf-B (closed), the orientation is towards the Zn2+ ion. Substrate binding and structural analysis, detailed overview. In both QC isozymes, three acidic residues (E201, D248, and D305 in sQC, and E225, D269 and D326 in gQC) are pointed to each other and are likely to form hydrogen bonds between them. These residues play a major role in the catalysis. Residues C139 and C164 are not involved in catalysis. Catalytic reaction mechanism
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Busby, W.H.; Quackenbush, G.E.; Humm, J.; Youngblood, W.W.; Kizer, J.S.
An enzyme(s) that converts glutaminyl-peptides into pyroglutamyl-peptides. Presence in pituitary, brain, adrenal medulla, and lymphocytes
J. Biol. Chem.
262
8532-8536
1987
Bos taurus, Homo sapiens, Rattus norvegicus, Sus scrofa
brenda
Song, I.; Chuang, C.Z.; Bateman, J.R.C.
Molecular cloning, sequence analysis and expression of human pituitary glutaminyl cyclase
J. Mol. Endocrinol.
13
77-86
1994
Homo sapiens
brenda
Bateman, R.C., Jr.; Temple, J.S.; Misquitta, S.A.; Booth, R.E.
Evidence for essential histidines in human pituitary glutaminyl cyclase
Biochemistry
40
11246-11250
2001
Homo sapiens
brenda
Schilling, S.; Hoffmann, T.; Rosche, F.; Manhart, S.; Wasternack, C.; Demuth, H.U.
Heterologous expression and characterization of human glutaminyl cyclase: evidence for a disulfide bond with importance for catalytic activity
Biochemistry
41
10849-10857
2002
Homo sapiens
brenda
Schilling, S.; Manhart, S.; Hoffmann, T.; Ludwig, H.H.; Wasternack, C.; Demuth, H.U.
Substrate specificity of glutaminyl cyclases from plants and animals
Biol. Chem.
384
1583-1592
2003
Carica papaya, Homo sapiens
brenda
Booth, R.E.; Lovell, S.C.; Misquitta, S.A.; Bateman, R.C., Jr.
Human glutaminyl cyclase and bacterial zinc aminopeptidase share a common fold and active site
BMC Biol.
2
2
2004
Homo sapiens (Q16769), Homo sapiens
brenda
Schilling, S.; Hoffmann, T.; Manhart, S.; Hoffmann, M.; Demuth, H.U.
Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions
FEBS Lett.
563
191-196
2004
Carica papaya, Homo sapiens
brenda
Schilling, S.; Niestroj, A.J.; Rahfeld, J.U.; Hoffmann, T.; Wermann, M.; Zunkel, K.; Wasternack, C.; Demuth, H.U.
Identification of human glutaminyl cyclase as a metalloenzyme. Potent inhibition by imidazole derivatives and heterocyclic chelators
J. Biol. Chem.
278
49773-49779
2003
Homo sapiens (Q16769), Homo sapiens
brenda
Huang, K.F.; Liu, Y.L.; Cheng, W.J.; Ko, T.P.; Wang, A.H.
Crystal structures of human glutaminyl cyclase, an enzyme responsible for protein N-terminal pyroglutamate formation
Proc. Natl. Acad. Sci. USA
102
13117-13122
2005
Homo sapiens (Q16769), Homo sapiens
brenda
Booth, R.E.; Misquitta, S.A.; Bateman, R.C., Jr.
Human pituitary glutaminyl cyclase: expression in insect cells and dye affinity purification
Protein Expr. Purif.
32
141-146
2003
Bos taurus, Homo sapiens
brenda
Huang, K.F.; Liu, Y.L.; Wang, A.H.
Cloning, expression, characterization, and crystallization of a glutaminyl cyclase from human bone marrow: a single zinc metalloenzyme
Protein Expr. Purif.
43
65-72
2005
Homo sapiens
brenda
Cynis, H.; Schilling, S.; Bodnar, M.; Hoffmann, T.; Heiser, U.; Saido, T.C.; Demuth, H.
Inhibition of glutaminyl cyclase alters pyroglutamate formation in mammalian cells
Biochim. Biophys. Acta
1764
1618-1625
2006
Homo sapiens, Mus musculus
brenda
Buchholz, M.; Heiser, U.; Schilling, S.; Niestroj, A.J.; Zunkel, K.; Demuth, H.U.
The first potent inhibitors for human glutaminyl cyclase: synthesis and structure-activity relationship
J. Med. Chem.
49
664-677
2006
Homo sapiens
brenda
Huang, K.F.; Wang, Y.R.; Chang, E.C.; Chou, T.L.; Wang, A.H.
A conserved hydrogen-bond network in the catalytic centre of animal glutaminyl cyclases is critical for catalysis
Biochem. J.
411
181-190
2008
Homo sapiens
brenda
Cynis, H.; Scheel, E.; Saido, T.C.; Schilling, S.; Demuth, H.U.
Amyloidogenic processing of amyloid precursor protein: evidence of a pivotal role of glutaminyl cyclase in generation of pyroglutamate-modified amyloid-beta
Biochemistry
47
7405-7413
2008
Homo sapiens
brenda
Gontsarova, A.; Kaufmann, E.; Tumani, H.; Dressel, A.; Mandel, F.; Wiesmueller, K.H.; Kunert-Keil, C.; Brinkmeier, H.
Glutaminyl cyclase activity is a characteristic feature of human cerebrospinal fluid
Clin. Chim. Acta
389
152-159
2008
Homo sapiens
brenda
Cynis, H.; Rahfeld, J.U.; Stephan, A.; Kehlen, A.; Koch, B.; Wermann, M.; Demuth, H.U.; Schilling, S.
Isolation of an isoenzyme of human glutaminyl cyclase: retention in the Golgi complex suggests involvement in the protein maturation machinery
J. Mol. Biol.
379
966-980
2008
Homo sapiens
brenda
Schilling, S.; Zeitschel, U.; Hoffmann, T.; Heiser, U.; Francke, M.; Kehlen, A.; Holzer, M.; Hutter-Paier, B.; Prokesch, M.; Windisch, M.; Jagla, W.; Schlenzig, D.; Lindner, C.; Rudolph, T.; Reuter, G.; Cynis, H.; Montag, D.; Demuth, H.U.; Rossner, S.
Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimers disease-like pathology
Nat. Med.
14
1106-1111
2008
Homo sapiens
brenda
Calvaresi, M.; Garavelli, M.; Bottoni, A.
Computational evidence for the catalytic mechanism of glutaminyl cyclase. A DFT investigation
Proteins
73
527-538
2008
Homo sapiens (Q16769)
brenda
Seifert, F.; Schulz, K.; Koch, B.; Manhart, S.; Demuth, H.U.; Schilling, S.
Glutaminyl cyclases display significant catalytic proficiency for glutamyl substrates
Biochemistry
48
11831-11833
2009
Carica papaya, Homo sapiens, Mus musculus, Solanum tuberosum
brenda
Stephan, A.; Wermann, M.; Von Bohlen, A.; Koch, B.; Cynis, H.; Demuth, H.; Schilling, S.
Mammalian glutaminyl cyclases and their isoenzymes have identical enzymatic characteristics
FEBS J.
276
6522-6536
2009
Homo sapiens, Mus musculus
brenda
Buchholz, M.; Hamann, A.; Aust, S.; Brandt, W.; Boehme, L.; Hoffmann, T.; Schilling, S.; Demuth, H.U.; Heiser, U.
Inhibitors for human glutaminyl cyclase by structure based design and bioisosteric replacement
J. Med. Chem.
52
7069-7080
2009
Homo sapiens (Q16769), Homo sapiens
brenda
Hartlage-Ruebsamen, M.; Morawski, M.; Waniek, A.; Jaeger, C.; Zeitschel, U.; Koch, B.; Cynis, H.; Schilling, S.; Schliebs, R.; Demuth, H.U.; Rossner, S.
Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Abeta deposits in hippocampus via distinct cellular mechanisms
Acta Neuropathol.
121
705-719
2011
Homo sapiens, Mus musculus
brenda
Ruiz-Carrillo, D.; Koch, B.; Parthier, C.; Wermann, M.; Dambe, T.; Buchholz, M.; Ludwig, H.H.; Heiser, U.; Rahfeld, J.U.; Stubbs, M.T.; Schilling, S.; Demuth, H.U.
Structures of glycosylated mammalian glutaminyl cyclases reveal conformational variability near the active center
Biochemistry
50
6280-6288
2011
Homo sapiens (Q16769), Mus musculus (Q9CYK2)
brenda
Koch, B.; Buchholz, M.; Wermann, M.; Heiser, U.; Schilling, S.; Demuth, H.U.
Probing secondary glutaminyl cyclase (QC) inhibitor interactions applying an in silico-modeling/site-directed mutagenesis approach: implications for drug development
Chem. Biol. Drug Des.
80
937-946
2012
Homo sapiens (Q16769), Mus musculus (Q9CYK2)
brenda
Huang, K.F.; Liaw, S.S.; Huang, W.L.; Chia, C.Y.; Lo, Y.C.; Chen, Y.L.; Wang, A.H.
Structures of human Golgi-resident glutaminyl cyclase and its complexes with inhibitors reveal a large loop movement upon inhibitor binding
J. Biol. Chem.
286
12439-12449
2011
Homo sapiens, Homo sapiens (Q9NXS2)
brenda
Cynis, H.; Funkelstein, L.; Toneff, T.; Mosier, C.; Ziegler, M.; Koch, B.; Demuth, H.U.; Hook, V.
Pyroglutamate-amyloid-beta and glutaminyl cyclase are colocalized with amyloid-beta in secretory vesicles and undergo activity-dependent, regulated secretion
Neurodegener. Dis.
14
85-97
2014
Bos taurus, Homo sapiens
brenda
Bridel, C.; Hoffmann, T.; Meyer, A.; Durieux, S.; Koel-Simmelink, M.A.; Orth, M.; Scheltens, P.; Lues, I.; Teunissen, C.E.
Glutaminyl cyclase activity correlates with levels of Abeta peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimers disease patients
Alzheimers Res. Ther.
9
38
2017
Homo sapiens (Q16769), Homo sapiens
brenda
Bender, P.; Egger, A.; Westermann, M.; Taudte, N.; Sculean, A.; Potempa, J.; Moeller, B.; Buchholz, M.; Eick, S.
Expression of human and Porphyromonas gingivalis glutaminyl cyclases in periodontitis and rheumatoid arthritis-A pilot study
Arch. Oral Biol.
97
223-230
2019
Porphyromonas gingivalis, Homo sapiens (Q16769), Homo sapiens (Q9NXS2), Homo sapiens
brenda
Li, M.; Dong, Y.; Yu, X.; Zou, Y.; Zheng, Y.; Bu, X.; Quan, J.; He, Z.; Wu, H.
Inhibitory effect of flavonoids on human glutaminyl cyclase
Bioorg. Med. Chem.
24
2280-2286
2016
Homo sapiens (Q16769), Homo sapiens
brenda
Ngo, V.T.H.; Hoang, V.H.; Tran, P.T.; Van Manh, N.; Ann, J.; Kim, E.; Cui, M.; Choi, S.; Lee, J.; Kim, H.; Ha, H.J.; Choi, K.; Kim, Y.H.; Lee, J.
Structure-activity relationship investigation of Phe-Arg mimetic region of human glutaminyl cyclase inhibitors
Bioorg. Med. Chem.
26
3133-3144
2018
Homo sapiens (Q16769), Homo sapiens
brenda
Wu, Z.; Weng, L.; Zhang, T.; Tian, H.; Fang, L.; Teng, H.; Zhang, W.; Gao, J.; Hao, Y.; Li, Y.; Zhou, H.; Wang, P.
Identification of glutaminyl cyclase isoenzyme isoQC as a regulator of SIRPalpha-CD47 axis
Cell Res.
29
502-505
2019
Homo sapiens (Q9NXS2)
brenda
Xu, A.; He, F.; Yu, C.; Qu, Y.; Zhang, Q.; Lv, J.; Zhang, X.; Ran, Y.; Wei, C.; Wu, J.
The development of small molecule inhibitors of glutaminyl cyclase and isoglutaminyl cyclase for Alzheimers disease
ChemistrySelect
4
10591-10600
2019
Homo sapiens (Q16769), Homo sapiens (Q9NXS2)
-
brenda
Schlenzig, D.; Cynis, H.; Hartlage-Ruebsamen, M.; Zeitschel, U.; Menge, K.; Fothe, A.; Ramsbeck, D.; Spahn, C.; Wermann, M.; Rossner, S.; Buchholz, M.; Schilling, S.; Demuth, H.U.
Dipeptidyl-peptidase activity of meprin beta links N-truncation of Abeta with glutaminyl cyclase-catalyzed pGlu-Abeta formation
J. Alzheimers Dis.
66
359-375
2018
Homo sapiens (Q16769), Homo sapiens
brenda
Pozzi, C.; Di Pisa, F.; Benvenuti, M.; Mangani, S.
The structure of the human glutaminyl cyclase-SEN177 complex indicates routes for developing new potent inhibitors as possible agents for the treatment of neurological disorders
J. Biol. Inorg. Chem.
23
1219-1226
2018
Homo sapiens (Q16769), Homo sapiens (Q9NXS2), Homo sapiens
brenda
Hielscher-Michael, S.; Griehl, C.; Buchholz, M.; Demuth, H.U.; Arnold, N.; Wessjohann, L.A.
Natural products from microalgae with potential against Alzheimers disease sulfolipids are potent glutaminyl cyclase inhibitors
Mar. Drugs
14
203
2016
Homo sapiens (Q16769)
brenda
Logtenberg, M.E.W.; Jansen, J.H.M.; Raaben, M.; Toebes, M.; Franke, K.; Brandsma, A.M.; Matlung, H.L.; Fauster, A.; Gomez-Eerland, R.; Bakker, N.A.M.; van der Schot, S.; Marijt, K.A.; Verdoes, M.; Haanen, J.B.A.G.; van den Berg, J.H.; Neefjes, J.; van den Berg, T.K.; Brummelkamp, T.R.; Leusen, J.H.W.; Scheeren, F.A.; Schumacher, T.N.
Glutaminyl cyclase is an enzymatic modifier of the CD47-SIRPalpha axis and a target for cancer immunotherapy
Nat. Med.
25
612-619
2019
Homo sapiens (Q9NXS2)
brenda
Vijayan, D.K.; Zhang, K.Y.J.
Human glutaminyl cyclase Structure, function, inhibitors and involvement in Alzheimers disease
Pharmacol. Res.
147
104342
2019
Homo sapiens (Q16769), Homo sapiens (Q9NXS2), Homo sapiens
brenda
Tran, P.; Hoang, V.; Lee, J.; Hien, T.; Tung, N.; Ngo, S.
In vitro and in silico determination of glutaminyl cyclase inhibitors
RSC Adv.
9
29619-29627
2019
Homo sapiens (Q16769)
-
brenda